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OBJECTIVES: Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are highly 
comorbid conditions that are affected by psychological factors, such as self-efficacy. 
Psychological factors can either hinder or promote medical interventions. Self-efficacy, the 
belief that one is able to make changes necessary for self-management, is associated with 
glycemic control and cardiac symptom burden, as well as behaviors that affect CAD prevention 
and outcomes.  
METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes 
(BARI 2D) trial, we assessed the relationship between self-efficacy and the treatment, risk factor 
control, and cardiac outcomes of patients with T2DM and CAD.  
RESULTS: The first paper (N=889) showed no significant relationships between self-efficacy 
and randomized treatment for CAD (revascularization vs. medical therapy β=0.06, p=0.66) and 
T2DM (insulin sensitizers vs. insulin providers β=0.06, p=0.65) in patients with baseline self-
efficacy scores ≤8.  The second paper (N=1,562) verified a negative association between 
baseline self-efficacy and follow-up HbA1c (β=-0.03, p<.001) and a positive association with 
self-efficacy and physical functioning in which time negatively modified the association 
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(interaction p=0.02). A lagged association (feedback loop) was shown between self-efficacy and 
HbA1c, physical functioning, and BMI over time. The feedback loops were stronger in White 
non-Hispanic patients compared to minority patients. In the third paper (N=1,817), poor baseline 
self-efficacy was associated with an increased risk of a composite endpoint of death/myocardial 
infarction/stroke (hazard ratio [HR] =1.34, p=0.01), subsequent revascularizations (HR=1.30, 
p=0.004), subsequent PCIs (HR=1.43, p<.001), and angina (odds ratio [OR] =1.11, p<.001) 
compared to Fair-Excellent self-efficacy, but not after adjusting for baseline covariates. A 
decrease in self-efficacy from baseline to Year 1 was positively associated with all-cause 
mortality (adjusted HR=2.32, p<.001) and death/MI/stroke (adjusted HR=1.79, p<.001).    
CONCLUSIONS: In summary, self-efficacy was associated with clinical risk factors and cardiac 
outcomes in patients with CAD and T2DM. This is of public health significance because it 
stresses the importance of improving a patient’s confidence in managing their conditions outside 
of the medical setting. 
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 1.0  SPECIFIC AIMS 
Despite the comorbid nature of T2DM and CAD, self-efficacy has not been studied in persons 
with both of these conditions, nor has it been studied longitudinally. Most studies have focused 
on self-efficacy in persons with CAD and in persons with T2DM, and are cross-sectional in 
design. Given the variety of therapies used to treat these conditions, it is not known whether self-
efficacy varies by the type of glycemic control (insulin-sensitizing drugs versus insulin-
providing drugs) or by the extent of glycemic control as measured by hemoglobin A1c (HbA1c). 
In addition, little is known about cardiac treatment and the psychological factors of self-efficacy 
in persons with T2DM and CAD.  
The objective of the study is to examine how self-efficacy is related to the management, 
treatment, and clinical outcomes of persons with both T2DM and CAD using data from the 
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. BARI 2D is a 
National Institutes of Health (NIH)-sponsored, multi-center, randomized clinical trial of patients 
with T2DM and angiographically-documented stable CAD. The proposed research topics to be 
addressed are: 
1. How does self-reported self-efficacy differ between patients on insulin-sensitizing 
drug therapy compared to insulin-providing drug therapy over time? How does self-
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 efficacy differ between patients whose CAD was treated with initial cardiac 
revascularization compared to initial medical therapy over time? 
2. What is the relationship between self-efficacy and the clinical risk factors of HbA1c, 
blood pressure, low density lipids (LDL), and physical functioning over time? Does 
race/ethnicity serve as an effect modifier for these associations? 
3. What is the relationship between self-efficacy and clinical endpoints (death, a 
composite of death/myocardial infarction [MI]/stroke, subsequent revascularizations, 
and angina) in patients overall and by type of randomized cardiovascular therapy 
(medical therapy or immediate revascularization)? 
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 2.0  INTRODUCTION 
The management of T2DM and CAD is not uniform and is a multifaceted process. Universally, 
all patients must make lifestyle changes that involve diet, exercise, foot care, and medication 
adherence. The various types of medication and hospital interventions include a diverse range of 
therapies, each differing in patient-physician involvement, pain, relief of pain, and complexity. 
The level of difficulty involved in managing one’s health can be the pivotal transitioning factor 
that advances a person from knowing (s)he should do a behavior, to the assessment of his or her 
ability to carry out the behavior, and finally to the execution and maintenance of that behavior 
according to social learning theory (Albert Bandura, 1991). Maintenance/adherence is influenced 
by both behavior difficulty and outcome satisfaction.  
To provide a better of understanding of the topics of interest, the background chapter will 
present the definition and epidemiology of T2DM, CAD, and self-efficacy.  It will also include 
the risk factors, management, and complications of T2DM and CAD. Next, the literature review 
will address studies that provide the basis for the proposed objectives.  These articles focus on 
what is known in the literature regarding psychosocial factors related to CAD and T2DM, and 
how the proposed objectives can address what is not known. This will be followed by a 
description of the BARI 2D study and its data, which were used for the analyses.  
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 This research is important to both patients and healthcare professionals. From the patient’s 
perspective, it explains why some people are likely to adhere to a physician's request. However, 
from the health professional’s perspective, it explains why certain treatment not only aids 
patients, but also how it helps their self-confidence to manage other comorbid conditions.  BARI 
2D provides a strong setting to investigate the role of self-efficacy, treatment, and treatment 
outcomes in patients with comorbid diseases. 
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2.1 BACKGROUND 
2.1.1 Type 2 Diabetes Mellitus 
2.1.1.1 Definition 
Diabetes mellitus is a metabolic disorder defined by chronic hyperglycemia (high blood sugar) 
and the inability to properly secrete or metabolize glucose.  Characteristic symptoms of diabetes 
mellitus include polydipsia (increased thirst), polyuria (increased frequency in urination), 
polyphagia (increased appetite), blurred vision, and weight loss (Alberti, Zimmet, & 
Consultation, 1998; Engelgau, et al., 2004). There are two major types of diabetes: 1) Type 1 
diabetes in which the onset is primarily in childhood; and 2) Type 2 diabetes (T2DM) in which 
the onset is primarily after the age of 45 years, but can occur at any age (Alberti, et al., 1998). 
T2DM begins with the body’s resistance to insulin production (ADA, 2009). In order to 
compensate, the pancreas over-secretes insulin to the point at which it can no longer effectively 
produce enough.  This proposal will focus only on T2DM, because it is the most prevalent form 
of diabetes mellitus.  
2.1.1.2 Epidemiology  
Approximately 23.6 million people in America have T2DM (17.9 million diagnosed and 5.7 
million undiagnosed), and the lifetime prevalence is 17% (NIDDK, 2007). This is not only a 
growing problem in America, but across the world. It is estimated that 125 million people 
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 worldwide have diabetes, with over 90% of the cases being T2DM. Due to environmental, 
behavioral, lifestyle, and dietary changes, the prevalence of T2DM worldwide continues to 
increase at an epidemic rate. Projections state that by the year 2025, 324 million people will have 
T2DM (Zimmet, 2003; Zimmet, Alberti, & Shaw, 2001).  
2.1.1.3 Risk Factors  
Non-modifiable risk factors for T2DM include having a family history of diabetes, being of 
racial/ethnic minority status, and older age (ADA, 2004, 2009; Engelgau, et al., 2004). 
Modifiable risk factors include being overweight, having a sedentary lifestyle, and poor diet. 
Additional risk factors for T2DM include: 1) pre-diabetes, a condition in which hemoglobin 
HbA1c levels are higher than normal (7.0%), but not high enough for a clinical diagnosis of 
T2DM; 2) gestational diabetes, which occurs during pregnancy; 3) delivering a baby over nine 
pounds; and 4) polycystic ovary syndrome. If left untreated through lack of diet modification and 
exercise, pre-diabetes can eventually progress into T2DM.  
2.1.1.4 Management  
Management of T2DM includes glycemic control and control of CAD risk factors such as high 
levels of low density lipids (>100) and hypertension (130/80 mmHg). This management protocol 
is known as the "ABCs" of diabetes care – normal levels of HbA1c (<7%), aggressive 
management of Blood pressure and additional cardiovascular risk factors (i.e., dyslipidemia and 
microalbuminuria), and normal Cholesterol levels through medications and lifestyle 
interventions (Gavin, Peterson, & Warren-Boulton, 2003; Ripsin, Kang, & Urban, 2009; 
Wattana, Srisuphan, Pothiban, & Upchurch, 2007).  
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 T2DM is defined by the body’s resistance to insulin, decreased insulin secretion, and 
increased hepatic glucose output (Ripsin, et al., 2009). Diabetes is commonly treated with 
insulin-sensitizing therapy, insulin-providing therapy, or a combination therapy.  Both insulin-
sensitizing drugs and insulin-providing drugs are equally efficient in managing T2DM in persons 
with CAD (BARI_2D_Study_Group, 2009). Insulin-sensitizing drugs such as thiazolidinediones 
and Biguanide (metformin) make fat, muscle, and liver cells more sensitive to the body’s natural 
insulin and decrease hepatic glucose output (Magee & Isley, 2006).  They are taken orally in the 
form of a pill. Insulin sensitizers are often used as first line agents in patients whose T2DM is 
fairly under control.  Insulin drug use is indicative of treatment for more severe diabetes. Insulin 
drugs either provide the body with insulin or stimulate the pancreas to produce more insulin 
(insulin secretagouges) (Magee & Isley, 2006). Insulin comes in liquid form and as a suspension 
that is injected subcutaneously, several times a day (American_Society_of_Health-
System_Pharmacists, 2009).  It can be prescribed in conjunction with insulin-sensitizing drugs to 
assist in glycemic control (Ripsin, et al., 2009).  
2.1.1.5 T2DM Complications 
If untreated or poorly managed, T2DM can result in blindness, amputations, end stage renal 
disease (ESRD), and cardiovascular complications such as myocardial infarction (heart attack) 
and stroke (NIDDK, 2007). In 2004, CAD disease accounted for 68% of the deaths in people 
with T2DM aged 65 years or older (NIDDK, 2007). Based on 20 years of surveillance data, the 
Framingham Heart Study found that patients with diabetes had a two- to three-fold increased risk 
of CAD compared to patients without diabetes (Kannel & McGee, 1979). 
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 2.1.2 Coronary Artery Disease 
2.1.2.1 Definitions 
Coronary artery disease (CAD) is characterized by atherosclerotic plaque build-up in the arteries, 
resulting in inadequate circulation of blood to the heart, brain, and surrounding tissues. 
Atherosclerosis is a condition that begins in childhood as a fatty streak within the endothelial 
cells, and due to years of accumulation of low density lipoproteins (LDL) and triglycerides, 
macrophage white blood cells, and other fatty deposits. It progresses throughout adulthood into 
calcification and/or a lesion(s). CAD is a specific type of cardiovascular disease. Cardiovascular 
disease is a class of diseases that affects the cardiovascular system – the heart, arteries, and 
veins. Types of cardiovascular disease include coronary heart disease, congestive heart failure 
(CHF), angina, aneurysm, peripheral vascular disease, myocardial infarction (MI), and stroke. 
MI and stroke are also considered to be adverse outcomes of cardiovascular disease.   
MI is a rapid necrosis of the myocardium due to interrupted blood flow from the arteries. 
The plaque in an atherosclerotic artery can rupture with thrombus (blood clot) formation, 
occluding blood flow. This results in the severe inability of the artery to meet the oxygen the 
demands of the heart (ischemia). Without proper medical response within 20 to 40 minutes, 
irreversible death of the myocardium results. The myocardium will continue to die for six to 
eight hours, and scar tissue forms in its place (Burke & Virmani, 2007).  
A stroke (cerebrovascular accident) is developing brain damage caused by interrupted 
blood flow to the brain due to a hemorrhage (bleeding in the brain) or ischemia (restricted blood 
flow). The brain suffers from a lack of oxygen and necrosis results. Warning signs of a stroke 
include sudden: 1) numbness or weakness of the face, arm, or leg, especially on one side of the 
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 body;  2) confusion, trouble speaking or understanding; 3) vision problems in one or both eyes; 
4) trouble with gait, balance, and coordination; and 5) severe headache. Depending on the 
affected area of the brain and the severity of the damage, a stroke can result in mild to severe 
paralysis, aphasia (loss of speech or comprehension of speech), or blindness in one side of the 
visual field (AHA, 2009a). 
Angina is a  treatable cardiovascular complication characterized by marked intermittent chest 
pain due to reduced oxygen to the heart (Campeau, 1975). Classic angina as defined by the 
Canadian Cardiovascular Society (CCS) Functional Classification of Angina is based on the 
activity that evokes pain and physical limitations (Campeau, 1975): 
• Class I: Prolonged exertion, no physical limitations 
• Class II: Walking more than two blocks or more than one flight of stairs, slight physical 
limitations 
• Class III: Walking more than two blocks or more than one flight of stairs, marked 
physical limitations 
• Class IV: Minimal or at rest, severe physical limitations 
Angina equivalents are a group of symptoms other than angina such as light headedness, 
dyspnea, or pain in the arm or jaw (MediLexicon_International_Ltd, 2009).  
2.1.2.2 Epidemiology 
Approximately 80 million adults in America (approximately 1 in 3) have some form of CAD, 
and CAD was the leading cause of death in 2005 (CDC, 2008). In fact, CAD and cancer are the 
leading causes of morbidity and mortality in industrialized countries, and are steadily eclipsing 
infectious disease and malnutrition worldwide (CDC, 2008). 
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 2.1.2.3 Risk Factors 
Non-modifiable risk factors for CAD include being of racial/ethnic minority status, male sex, 
older age, and having a family history of CAD (especially before the age of 60). Modifiable risk 
factors are smoking/smoke exposure, high cholesterol, T2DM, sedentary lifestyle, high body 
mass index, unhealthy diet, and hypertension (AHA, 2009a). These risk factors are similar to 
those of T2DM, which partially explains why these two chronic conditions are often comorbid. 
Despite these shared risk factors, data from the National Health and Nutrition Examination Study 
(NHANES) showed that the reduction in CAD risk factors and improved heart disease treatment 
was less effective in reducing mortality in people with T2DM compared to those without T2DM, 
especially in women (CDC, 1996; Gu, Cowie, & Harris, 1999). 
2.1.2.4 Treatment 
Treatment options for CAD include 1) medical management with diet, exercise, and medicine; 
and/or 2) revascularization either by CABG or PCI. CABG is an invasive procedure in which a 
healthy blood vessel is grafted onto the heart to bypass the blocked part of the coronary artery. 
This attached artery improves blood flow to the heart muscle. Depending on the number of 
blocked arteries, patients can have multiple grafts (AHA, 2009). PCI is a less invasive procedure 
in which a balloon–tipped catheter is placed into the diseased artery of the heart (AHA, 2009). 
The balloon is inflated, which compresses the plaque in the arterial wall in order to widen the 
lumen and improves blood flow. Often, a bare metal stent or drug eluting stent (mesh wire tube) 
is inserted to prop open the inflated arteries (AHA, 2009a). 
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 2.1.2.5 CAD Complications 
Adverse outcomes that are commonly associated with CAD are MI, stroke, and angina.  These 
can result in death, disability, and/or reduced quality of life. The risk of CAD-related 
complications in those with T2DM is 2 to 4 times greater compared to those without T2DM 
(Stamler, Vaccaro, Neaton, & Wentworth, 1993). Compared to persons with CAD only, persons 
with T2DM and CAD have increased mortality and experience far worse clinical outcomes as a 
result of CAD events and revascularization (Deaton, et al., 2006; Sobel, Frye, & Detre, 2003). 
Psychological factors, such as depressive symptom severity, increase CAD risk factors and the 
risk of adverse cardiovascular events (Rutledge, et al., 2006).  
2.1.3 Self-efficacy 
The confidence to successfully make change is known as self-efficacy (Bandura, 1977). Patients 
with both T2DM and CAD must engage in daily regimens in order to make positive changes in 
their health and decrease their risk of disease-related morbidities. Therefore, self-efficacy is a 
critical part of disease self-management (Anderson, Funnell, Fitzgerald, & Marrero, 2000).   
The concept of “readiness to change” was coined by Bandura (1977) as one construct in 
his social cognitive theory of human behavior and learning.  The foundation of this theory rests 
on “reciprocal determinism,” which states that a person’s behavior shapes their environment, 
which in turn shapes the person’s behavior. Social learning occurs when people learn through 
observing other’s behaviors, attitudes, and outcomes due to the behaviors. In order to have 
effective modeling, the following conditions must be met: 1) attention to the behavior, 2) 
retention regarding the behavior, 3) reproduction of the behavior, and 4) motivation (a cause to 
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imitate the behavior). Whether or not one decides if the behaviors should be and can be modeled 
is strongly based on self-efficacy (Albert Bandura, 1991). 
Over time, consensus emerged around the term “self-efficacy” to define a person’s 
confidence in being able to make change (A. Bandura, 1977, 1982). Within the concept of self-
efficacy, mastery of a required skill gives one confidence to continue to utilize this skill. Self-
efficacy arises from: 1) performance accomplishments (how well they have controlled their 
T2DM and CAD); 2) vicarious experience (fellow patients’ experiences in self-management); 3) 
verbal persuasion (medical advice); and 4) physiological states (emotional arousal in coping with 
threatening situations) (A. Bandura, 1977, 1982). Self-efficacy differs from outcome 
expectancies in that it focuses on the belief in one’s skills in performing an act, rather than the 
outcome of the act itself (Figure 1) (A. Bandura, 1977, 1982). A person can believe that an act 
will produce a desired outcome, but if she or he does not believe the act can be mastered, then 
the behavior will not be executed. Expectations of self-efficacy determine whether or not the 
self-management behaviors will commence, how long they will be done, and whether or not they 
will persist during obstacles and difficult circumstances (A. Bandura, 1977, 1982). This is of 
importance to the medical field because one’s belief that she or he is able to effectively manage 
his or her health mediates change, and these beliefs are readily stimulated and formed by one’s 
successes with self-management of the diseases (Anderson, et al., 2000; A. Bandura, 1977). 
Frequently, patients perceive barriers to active self-management of chronic conditions. 
Depression, difficulty exercising, poor communication with healthcare professionals, low family 
support, physical pain, and financial problems are the most commonly documented barriers 
(Jerant, Friederichs-Fitzwater, & Moore, 2005). Furthermore, the lack of drive to fully engage in 
 the regimens related to chronic conditions can result in poor outcomes and additional utilization 
of the medical system (Jerant, et al., 2005). The relationship between drive and outcomes is 
consistent among age groups, literacy levels, and races (Rika Nakahara, et al., 2006; Sarkar, 
Fisher, & Schillinger, 2006).  
 
PERSON BEHAVIOR OUTCOME 
Efficacy Expectations 
- Performance accomplishments 
- Vicarious experience 
- Verbal persuasion 
- Emotional arousal 
Outcome Expectations 
Figure 1. Author’s schematic diagram based on Bandura’s conceptual model of self-
efficacy (A. Bandura, 1977) 
Bandura’s model was the theoretical context for development of the Chronic Disease Self 
Management Program launched by researchers at Stanford University (Lorig, 1996). They 
realized that the effectiveness of chronic disease management is highly contingent upon the self-
care behaviors of the patients. This program has been shown to improve self-efficacy, self-
management behaviors, and health outcomes, as well as reduce hospitalizations. Therefore, it is 
important to understand the interaction between chronic conditions such as T2DM and CAD and 
the patients’ self-management behaviors in order to improve their health outcomes (Deaton, et 
al., 2006; Sansing, 2007).  
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 2.2 LITERATURE REVIEW 
The search for appropriate articles regarding T2DM, CAD, and self-efficacy was undertaken 
using the MEDLINE database through the PubMed database from July 2009 – November 2009. 
The following guidelines apply to all articles in the literature review. Search results were limited 
to English publications and human studies in adults aged 19 years and older. Through the 
evaluation of the abstracts, editorials were removed as well as articles relating to “numeracy,” 
“education tools,” and “assessment development.” 
 
2.2.1 Self Efficacy and Type 2 Diabetes Management 
Multiple studies have shown that self-efficacy may enhance self-management behaviors that in 
turn influence glycemic control (Table 1). The majority of studies reported that self-efficacy was 
positively associated with better self-care behaviors such as a higher frequency of blood glucose 
testing and diet and medication adherence, but was not directly associated with glycemic control 
(Aljasem, Peyrot, Wissow, & Rubin, 2001; Chlebowy & Garvin, 2006b; R. Nakahara, et al., 
2006; Nelson, McFarland, & Reiber, 2007; Sousa, Zauszniewski, Musil, Price Lea, & Davis, 
2005). One study showed that “[s]elf-efficacy explained 4% to 10% of the variance in diabetes 
self-care behaviors beyond that accounted for by patient characteristics and health beliefs about 
barriers [to care]" (Aljasem, et al., 2001). Patients whose self-efficacy was enhanced through 
self-management skills saw a greater decrease in mean HbA1c (8.08% to 7.40%) after 24 weeks 
compared to patients without self-management skill training (8.09% to 8.02%), and were more 
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 likely to reach the HbA1c goal of <7% as recommended by the American Diabetes Association 
(ADA) (ADA, 2004; Chodchoi, Wichit, Linchong, & Sandra, 2007). Part of Bandura’s theory 
states that a positive outcome reinforces self-efficacy, so better glycemic control can serve to 
improve one’s self-efficacy over time. However, Chlebowy et al. (2006a) examined the 
relationship between psychosocial factors and self-care behaviors and glycemic management in 
Black and White patients. Outcome expectancy was related to self-care behaviors. Although 
Black patients reported less satisfaction with social support than did White patients, there were 
no difference between the races regarding self-efficacy, which was unrelated to self-care 
behaviors and glycemic control (Chlebowy & Garvin, 2006c). 
Non-adherence to oral diabetes medications is one of the leading factors for poor 
glycemic management (Guillausseau, 2003). In one study, patients on oral medications had 
higher measures of self-efficacy regarding motivation to change and ability to cope with feelings 
than patients on insulin (Via & Salyer, 1999).  In an additional study, lower self-efficacy was 
related to the burden of injecting insulin (OR=2.48; 95% confidence interval [CI] 1.27– 4.84) 
and the burden of adjusting insulin (OR=1.89; 95% CI 1.17– 3.05) (Iris Weijman, et al., 2005).  
2.2.1.1 Strengths and Limitations 
Despite the variety of assessments used, samples sizes, and populations, most studies centered on 
the same conclusion: self-efficacy is indeed related to the behaviors that affect glycemic control. 
The prospective randomized controlled trials were able to assess direction and causality between 
self-efficacy and glycemic control (Siebolds, Gaedeke, & Schwedes, 2006; Wattana, et al., 
2007). Also, the studies were conducted among different races in the US, and in Japan, Germany, 
and Thailand, extending the generalizability of the results to people of different races and 
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 nationalities (Chlebowy & Garvin, 2006b; R. Nakahara, et al., 2006; Siebolds, et al., 2006; 
Wattana, et al., 2007). The study by Chlebowy et al. had a methodologically sound study design, 
but had a small sample size, which could limit its ability to detect statistical differences (N=91). 
In addition, studies took into consideration the different types of behaviors associated with 
glycemic control therapy (oral medications versus insulin). 
The main limitation was the cross-sectional design of several studies. Therefore, these 
results could not be used to establish causality or direction of association. The act of glycemic 
management varies by the use of oral medication or injectable insulin. It is still unclear whether 
self-efficacy differs by the type of glycemic therapy due to the lack of randomization of 
glycemic management; therefore, the patients may have differed clinically by the type of insulin 
therapy prescribed by their physicians prior to entering the study.  The self-efficacy assessments 
were also self-reported. Although this is characteristic of most self-efficacy assessments, it may 
introduce social desirability bias, in which the respondent reports what she or he believes are the 
answers that will be desired by the study. Additionally, there is recall bias, in which the 
respondent’s ability to recall positive or negative experiences is skewed by the person’s desire to 
be seen as a good patient, or by poor memory.  
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 Table 1. Self-efficacy and T2DM management 
Key: DM – diabetes mellitus, SE – self-efficacy 
AUTHOR STUDY DESIGN SAMPLE SIZE SELF-EFFICACY ASSESSMENT 
MAJOR FINDING(S) / RESULTS 
(PRIMARILY WITH RESPECT TO 
SELF-EFFICACY) 
(Aljasem, et 
al., 2001) 
Cross-sectional, 
correlational 
(N=309) Modified version of 
Grossmans Self-Efficacy for 
Diabetes scale 
Greater self-efficacy was associated 
with a higher frequency of blood 
glucose testing and better medication 
adherence and eating habits. SE 
explained 4% to 10% of the variance 
in diabetes self-care behaviors 
(Chlebowy & 
Garvin, 
2006b) 
Two-group, 
comparative 
descriptive design 
(N=91) Modified Self-efficacy 
Questionnaire (SEQ) 
Outcome expectancies were related to 
self-care behaviors, but SE was not 
related to glycemic control or self-
care behaviors 
(Chodchio et 
al. 2007) 
Longitudinal, 
randomized controlled 
trial 
DM 
management 
program 
(N=75) 
Control (N=72) 
DM management program 
based in Bandura’s theory of 
self-efficacy 
DM self-management program based 
in self-efficacy was associated with 
better glycemic control. 
(R. Nakahara, 
et al., 2006) 
Prospective (N=256) Multidimensional Diabetes 
Questionnaire with a 
Diabetes-Related Self-
Efficacy Scale 
SE was related to DM adherence 
which in turn was related to 
prospective HbA1c 
(Nelson, et al., 
2007) 
Cross-sectional survey (N=1,286) Perceived Competence in 
Diabetes Scale 
Higher self-efficacy was related to 
better medication and DM meal plan 
adherence, diet, physical activity, and 
blood glucose monitoring 
(Siebolds, et 
al., 2006) 
Prospective, 
randomized, 
controlled, multicenter 
parallel group 
comparison 
Self-monitoring 
device (N=113) 
Control 
(N=110) 
Diabetes counseling 
algorithm designed to 
improve, self-perception, self-
reflection and self-efficacy  
SE and diet counseling plus self-
monitoring of blood glucose was more 
efficient in glycemic control than 
counseling alone 
(Sousa, et al., 
2005) 
Cross sectional, 
correlation  
(N=141) Insulin Management Diabetes 
Self-efficacy Scale (IMDSES) 
Greater self-care agency and self-
efficacy? better self-care 
management ? greater glycemic 
control.Self-care management was not 
a mediator. 
(Via & Salyer, 
1999) 
Cross-sectional, 
descriptive, correlation 
(N=90) Diabetes Empowerment Scale 
(DES) 
Patients on oral medications had 
higher scores in motivation to change 
and ability to cope with feelings 
components of the DES than patients 
on insulin. Baseline HbA1c was not 
related to SE
(Wattana, et 
al., 2007) 
Randomized 
controlled trial 
Self-
management 
program 
(N=75) 
Usual nursing 
care (N=72) 
Self-management program 
based on Bandura’s theory of 
SE 
Patients in the diabetes self-
management program showed a better 
glycemic control and decreased 
cardiovascular risk factors, and 
improved quality of life. 
(Iris Weijman, 
et al., 2005) 
Cross-sectional, 
descriptive, correlation 
(N=292) Diabetes Management Self-
efficacy Scale 
Lower self-efficacy was related to the 
burden of injecting insulin and the 
burden of adjusting insulin 
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2.2.2 Self-efficacy of Diabetes and Cardiovascular Disease Comorbidity 
Deaton et al. (2006) studied symptom distress, self-management, and general and cardiac health 
status in 1,013 CAD patients with and without T2DM in the Clinical Outcomes Utilizing 
Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. Self-management was 
measured by the Self-Management Difficulties Scale (Crohnbach’s α = 0.89), which was adapted 
from the Environmental Barriers to Adherence Scale (EBAS) used to measure self-management 
of diabetes (Irvine, Saunders, Blank, & Carter, 1990).  
Researchers found the effects of both CAD and T2DM to be synergistic in hindering self-
management. Patients with T2DM and a greater severity of T2DM (HbA1c >7%) had more self-
management difficulty regarding medication, exercise, and diet. They also had more physical 
limitations that promoted the difficulties in self-management. CAD severity was the most 
important comorbid factor in explaining a poorer risk factor profile for physical disability in 
patients with T2DM, which was independently associated with increased odds of disability in 
this patient population. Variables found to be associated with self-management were age, angina 
status, severity of T2DM, renal disease, symptom distress, and social support (R2 = 0.12; p = 
0.03) (Deaton, et al., 2006). 
2.2.2.1 Strengths and Limitations 
The COURAGE Trial is comparable to the BARI 2D study in that it was composed of patients 
with stable CAD suitable for elective revascularization. The large sample size allowed for higher 
power to detect differences in self-efficacy between the groups. This study was limited in that it 
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 was cross-sectional and could not establish causality, and used mainly White male patients, 
thereby limiting the generalizability of the results to females and racial/ethnic minorities.   
 
2.2.3 Self-efficacy and Revascularization 
19 
Studies show that self-efficacy improves after revascularization and continues to improve with 
time; therefore, patients in BARI 2D who are randomized to immediate revascularization are 
hypothesized to have greater self-efficacy than patients randomized to immediate medical 
therapy (Table 2).  In a study by Aron et al. (2007), quality of life and self-efficacy significantly 
improved after off-pump and on-pump CABG (Aron, Klinger, & McConnell, 2007). In a 
population of patients with either PCI and/or MI and patients with the need for revascularization, 
both self-efficacy and health-related quality of life (HRQoL) increased over time after 
revascularization (Gardner, et al., 2003). Although men had greater self-efficacy than women, 
women showed the greatest improvements in self-efficacy over the course of the study. In 
addition, patients with a history of PCI had the highest mean self-efficacy scores, because their 
physical limitations were less prohibitive (Gardner, et al., 2003). In a longitudinal study of 
elderly patients with MI or who had undergone CABG, those patients who experienced MIs had 
greater mean self-efficacy at week 1 following revascularization (p<0.001), while patients who 
had undergone CABG had greater mean self-efficacy at week 12 (p<0.001). Mean self-efficacy 
expectation scores were moderately high post-procedure (percutaneous transluminal coronary 
angioplasty [PTCA]) for all self-management behaviors, and all scores increased significantly, 
except scores for resumption of work-roles, by two weeks post-discharge (Perkins & Jenkins, 
1998).  
 
 2.2.3.1 Strengths and Limitations 
Two of the studies reviewed were longitudinal, and were, therefore, able to assess self-efficacy 
before and after surgery, and compare the levels of self-efficacy several weeks post-surgery.  All 
studies included not only a variety of quality of life measures, but also physical performance 
measures, because CAD and revascularization affect physical ability. More specifically, post-
event physical disability is an issue in cardiac patients (Perkins & Jenkins, 1998).  
Most of the studies reviewed contained selection biases. The study by Aron et al. (2007) 
was a retrospective study of 295 cardiopulmonary rehabilitation patients who were able to attend 
at least 80% of the exercise sessions required by the study protocol, thereby possibly resulting in 
the selection of healthier patients.  Also, the study was not designed or powered to detect 
differences in self-efficacy before and after CABG, because this was not the primary hypothesis. 
The study by Gardener et al. (2003) was based on a non-randomized sample of convenience; 
therefore, the clinical and demographic profiles of the patients in each group may have differed. 
Also, part of the self-efficacy assessment assumed that patients were mobile (introducing 
selection bias by excluding non-mobile patients), and came with precautions against its 
generalizability to patients who were older, had lower socioeconomic status, and had greater 
cardiovascular impairments (Gardner, et al., 2003).  The sample size (N=90) and the 
convenience sample of married White males in the Perkins et al. (1998) study limit the 
generalizability of their results. 
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Table 2. Self-efficacy and CAD management 
 
AUTHOR STUDY DESIGN SAMPLE SIZE 
SELF-EFFICACY 
ASSESSMENT 
MAJOR FINDING(S) / RESULTS 
(PRIMARILY WITH RESPECT TO SELF-
EFFICACY) 
Aron, Klinger, & 
McConnell, 2007) 
Retrospective (N=259) “a self-efficacy tool” for 
physical performance 
Self-efficacy improved in patients post 
CABG regardless of off-pump or on-
pump surgery. 
Gardner et al., 2003 Longitudinal (N=472) 7-item SE questionnaire 
regarding physical 
functioning 
Self-efficacy improved over time 
following revascularization 
Men had higher self-efficacy, but 
women’s self-efficacy improved faster 
PCI patients’ self-efficacy progressed 
quickly. 
Perkins & Jenkins, 
1998 
Descriptive, 
correlation 
(N=90) Jenkins Self-Efficacy 
Expectation Scales 
SE scores improved post PTCA 
2.3 BARI 2D 
2.3.1 Study Design  
BARI 2D is a multicenter clinical trial designed to determine optimal treatment strategies for 
patients with T2DM and documented stable CAD. Using a 2x2 factorial design, BARI 2D 
compared initial elective revascularization with aggressive medical therapy versus initial 
aggressive medical therapy and delayed revascularization, while simultaneously studying an 
insulin-providing versus an insulin-sensitizing strategy of glycemic control to achieve a clinical 
target of HbA1c <7% (Figure 2) (BARI_2D_Study_Group, 2006). 
Randomization to either immediate revascularization (REV) or initial medical 
management (MED) was stratified by BARI 2D site and by intended revascularization to either 
PCI or CABG as determined by a physician.  Patients who were randomized to immediate 
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revascularization were to receive an intervention by a BARI 2D certified technician within four 
weeks of randomization. Patients randomized to initial aggressive medical therapy were 
permitted to receive revascularization if their symptoms worsened or if there were cardiac 
events. All patients received aggressive medical therapy for cardiac risk factor control, such as 
dyslipidemia, hypertension, and angina, based on the BARI 2D protocol.  The protocol also 
included a non-pharmacologic Lifestyle Program aimed at smoking cessation, weight loss, foot 
care, and proper exercise.  
 
Enrolled in BARI 2D
N=2368
Coronary Angiogram Assessed
CABG Stratum
N=763
PCI Stratum
N=1605
Randomized Randomized
MED
N=385
REV
N=378
MED
N=807
REV
N=798
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IS
N=191
IP
N=194
IS
N=188
IP
N=190
IS
N=408
IP
N=399
IP
N=402
IS
N=396  
Key: IP – insulin providing, IS, insulin sensitizing, MED – medical therapy, REV – immediate revascularization 
Figure 2. BARI 2D enrollment and randomization.  
 
 Randomization to either insulin-sensitizing drugs or insulin-providing drugs required that 
patients adopt the assigned form of drug therapy, regardless of the form of therapy prior to study 
entry. Patients assigned to insulin-sensitizing drug therapy were to be treated with 
thiazolidinediones or metformin, while patients assigned to insulin-providing drug therapy were 
treated with sulfonylurea, repaglinide, nateglinide, or insulin (BARI_2D_Study_Group, 2006). If 
over the course of the study, a patient’s HbA1c remained >8%, (s)he was to receive glucose-
lowering drugs from the other treatment arm. Additional control of HbA1c was based on an 
algorithm for optimal glycemic control through combination therapy (Magee & Isley, 2006). 
At the baseline visit, extensive clinical, demographic, and psychosocial data were 
collected including education, employment status, height, weight, HbA1c, duration of T2DM, 
history of MI, blood pressure, lipid values, and number and type of medications. Study 
participants also completed a comprehensive battery of self-reported psychosocial measurements 
including four questions regarding their self-efficacy. 
Follow-up visits occurred monthly for the first six months and quarterly thereafter, until 
the end of the study in 2008. At each follow-up visit, information about clinical risk factors, 
diabetes complications, clinical events, and medications was collected.  The mean follow-up per 
patient was 5.3 years. The BARI 2D primary endpoint was all-cause mortality. The composite 
secondary endpoint was death, non-fatal MI, or stroke.  
2.3.2 Population 
Participants were enrolled between January 1, 2001 and March 31, 2005. There were 49 clinical 
sites in the United States (US), Canada, Brazil, Mexico, the Czech Republic, and Austria 
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 (N=2,368). Eligible participants had a “diagnosis of T2DM and angiographically documented 
CAD for which revascularization was not required for prompt control of severe or unstable 
angina” (BARI_2D_Study_Group, 2006). A physician/investigator at each site determined if the 
patients were eligible for the study based on the inclusion/exclusion criteria. Inclusion criteria 
were as follows: diagnosis of T2DM, coronary arteriogram showing one or more vessels 
amenable to revascularization (≥50% stenosis), objective documentation of ischemia or 
subjectively documented typical angina with ≥70% stenosis in at least one artery, suitability for 
coronary revascularization by at least one of the available methods, ability to perform all tasks 
related to glycemic control and risk factor management, age 25 or older, and informed written 
consent (BARI_2D_Study_Group, 2006). Exclusion criteria were as follows: definite need for 
invasive intervention as determined by a cardiologist, any CABG or PCI within the past 12 
months, class III or IV CHF, creatinine > 2.0 mg/dl., HbA1c > 13%, need for major vascular 
surgery concomitant with revascularization (e.g., carotid endarterectomy), left main stenosis > 
50%, non-cardiac illness limiting mortality, hepatic disease, fasting triglycerides >1,000 mg/dl in 
the presence of moderate glycemic control (HbA1c <9.0%), current alcohol abuse, chronic 
steroid use, known/planned/suspected pregnancy, geographically inaccessible or unable to return 
for follow-up, enrolled in a competing randomized trial or clinical study, and unable to 
understand or cooperate with protocol requirements (BARI_2D_Study_Group, 2006). 
 The recruitment pattern for patients differed according to site. Patients were generally 
recruited through screenings conducted in the cardiac catheterization laboratory, stress test 
laboratory, and outpatient clinics both inside and outside of the study sites. Because CAD and 
T2DM affect minorities disproportionately, there was a strong push to recruit at least 25% 
minority participants from the sites. Before randomization, it was required that all patients sign 
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 the informed consent document which also contained Health Insurance Portability and 
Accountability Act (HIPAA) information.  
BARI 2D patients were mostly White non-Hispanic (nH) males with a mean age of 
62.4±9 (Table 3). The majority of the patients were recruited from the U.S. (63%) and Canadian 
sites (15%).  Close to 30% of the patients were racial/ethnic minorities. About a third of the 
patients (27%) came into the study on insulin. In order to further examine the BARI 2D patient 
profile, the combination of cardiac risk factors and clinical history is presented in Figure 3. 
Forty five percent of the patients had the combined risk factors of hypertension, 
hypercholesterolemia, and smoking, nearly a third had a history of clinically documented MI, 
and seven percent had a history of CHF.  Less than a quarter of patients had a prior 
revascularization.  
Of the 2,368 randomized patients, 1,499 patients were from the US sites and 353 patients 
from the Canadian sites. Of these patients, 1,817 completed a baseline SE assessment (Figure 4).  
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Table 3. Baseline characteristics of BARI 2D population 
Baseline Demographic & Clinical Status (N = 2368) Baseline Demographic & Clinical Status (N = 2368) 
Age, mean, SD 62.4, 8.9 Hypertension, % 82.5 
Male, % 70.4 Hypercholesterolemia, % 81.9 
Race, %  Cigarette smoking status, %  
 White 70.4  Current 12.5 
 Black 17  Former 54.4 
 Asian 4.2  Never 33.1 
 Indian/Native American 4.3 Myocardial infarction, % 32 
 Other 4.1 Congestive heart failure, % 6.6 
Hispanic ethnicity, % 12.5 Stroke or TIA, % 9.8 
Region of World, %  Prior PCI, % 19.6 
 USA 63.3 Prior CABG, % 6.4 
 Canada 14.9 Angina status, %  
 Brazil 15  None 17.9 
 Mexico 3.6  Angina equivalents only 21.4 
 Czech Republic/Austria 3.2  Stable CCS 1 14.3 
BMI categories (kg/m2), %   Stable CCS 2 28.8 
 Normal or underweight, <25 9.7  Stable CCS 3 7.5 
 Overweight, 25 to <30 34  Stable CCS 4 1.2 
 Class 1 obese, 30 to <35 32.1  Unstable angina 9.5 
 Class 2 obese, 35 to <40 15.3 Duration of DM categories, %  
 Class 3 obese, ≥40 9  <5 yrs 33.3 
Blood pressure >130/80 mmHg,% 52.4  5 - <10 yrs 23.5 
Ankle brachial index ≤0.9 20.1  10 - <20 yrs 29.2 
Total cholesterol ≥200 mg/dL, % 19  ≥ 20 yrs 14.1 
Triglycerides ≥200 mg/dL, % 31 History of insulin use, % 29.3 
HDL <40 male <50 female mg/dL, % 72.4 Glycemia measurements, %  
LDL ≥100 mg/dL, % 40.5  HbA1c ≤ 7.0% 41.7 
Albuminuria   7.0% < HbA1c ≤ 8.0% 25.3 
 Microalbuminuria (30 < ACR ≤ 300) 22.9  HbA1c >8.0% 33 
 Macroalbuminuria (ACR > 300) 9.7 MNSI screening neuropathy score ≥7, % 15.9 
  MNSI clinical neuropathy score >2, % 50.3 
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Key to Table 3: ACR – albumin creatinine ratio, DM – type 2 diabetes mellitus, HbA1c – glycosylated hemoglobin A1c, HDL – 
high density lipids, LDL – low density lipids, MNSI – Michigan Neuropathy Screening Instrument 
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Key: CHF – congestive heart failure,  Htn – hypertension, Hchl – hypercholesterolemia, MI – myocardial infarction, PAD – 
peripheral artery disease, Smk – current smoker 
Figure 3. Observed combinations of cardiac risk factors and clinical history in the BARI 
2D population 
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Figure 4. Flowchart for study population 
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2.3.3 Variables 
Self-efficacy is the key measurement of one’s self-confidence in medical self-management. 
Thereby, it serves as the main psychological measure for this proposal.  At study entry, BARI 2D 
participants completed the self-efficacy questionnaire, as well as a comprehensive battery of 
psychosocial quality of life measures regarding their own health, self-rated health, energy, health 
distress, and ability to do different activities. Demographic information, clinical history, 
prescribed pharmaceuticals, and quality of life data were also collected.  
2.3.4 Measurements 
2.3.4.1 Self-efficacy 
Information regarding self-efficacy is part of the Quality of Life section of BARI 2D. The self-
efficacy assessment was administered at baseline and annually at Years 1 through 6 and was 
designed to measure how confident the patient was in his or her ability to do tasks and activities 
that relate to managing his or her T2DM and CAD in general and specific ways (Appendix A). 
The ambiguous term “management” may be interpreted as something as simple as trying to 
monitor glucose regularly or to adhering to a more complex regimen of a specific diet with 
regular exercise. Patients were encouraged to personally consider what tasks and activities he or 
she completed on a day-to-day basis, in order to measure confidence in the ability to keep T2DM 
and CAD “under control.”  
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 The self-efficacy assessment was derived from the Chronic Disease Self-management 
study and was found to have high internal consistency (Crohnbach’s α = 0.92) (Lorig, 1996). The 
questions were modified from disease management in general to address heart disease and 
T2DM specifically. Each question consisted of a 10-point Likert scale with “1 = not at all 
confident” and “10 = totally confident.” Interest lied in the patients’ confidence in: 1) doing all 
day-to-day things necessary to manage their conditions; 2) doing activities for their T2DM and 
CAD in order to reduce doctor visits; 3) reducing emotional stress associated with their diseases 
through acts such as prayer, meditation, art, and social contact; and 4) doing activities besides 
medication adherence, such as exercise, hobbies, and dieting to reduce the impact of the diseases 
on their daily life.  
2.3.4.2 Clinical Risk Factors 
HbA1c is used as a measure of diabetic severity, while LDL and systolic blood pressure are used 
as measures of cardiovascular risk. Resting blood pressure was measured with participants in the 
seated position. The systolic blood pressure and diastolic blood pressure reported are based on an 
average of the three sitting blood pressures. Hypertension is defined as a blood pressure level 
>140/90 mmHg (BARI_2D_Coordinating_Center, 2002-2005). Fasting total, LDL cholesterol, 
and high density lipid (HDL) cholesterol, fibrinolytic factors, insulin, and HbA1c levels were 
measured from blood samples collected at baseline and were analyzed at the BARI 2D core 
Biochemistry Laboratory. LDL was calculated using the Friedwald equation (Friedwald & 
Frederickson, 1972). Urine specimens were assayed at the Biochemistry Laboratory for albumin 
and creatinine in order to diagnose micro- and macroalbuminuria. Medication adherence was not 
measured in BARI 2D, only the types of medication prescribed. Patients with a history of health 
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 problems may be clinically under control, because of the medications they are using. Therefore, 
the medications used could serve as a surrogate for a history of the medical problems for which 
they are taking the medication (e.g., high LDL or high blood pressure). 
2.3.4.3 Primary and Secondary Endpoints  
The primary endpoint for BARI 2D trial was all-cause death and the secondary composite 
endpoint was death, nonfatal myocardial infarction, or stroke. Definitions for endpoints and 
ascertainment methods were provided in the main trial report (BARI 2D Study Group, 2006). 
Cause of death and stroke were classified and adjudicated by the BARI 2D Mortality and 
Morbidity committee. The committee was blinded to randomization assignment, treatment 
received, and additional clinical data.  Myocardial infarction was classified by a blinded 
independent Core Electrocardiography Laboratory.  
2.3.4.4 Quality of Life 
With self-rated health, patients are asked to rate their general health as either “Excellent,” “Very 
Good,” “Good,” “Fair,” or “Poor” (Ware & Sherbourne, 1992).  Health distress and energy were 
assessed by a 9-item questionnaire in which patients report how they have felt during the past 
four weeks (Stewart & Ware, 1992). Patients are read five answer options which range from “All 
of the Time” to “None of the Time.” The Duke Activity Status Index (DASI) is a 12-item 
questionnaire that measures the functionality of the patients in daily and recreational activities 
(Crohnbach’s α=0.67) (Dorian, et al., 2002). 
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 2.4  SUMMARY 
Several points are derived from the literature regarding the relationship of psychological factors 
with T2DM and CAD.  Higher self-efficacy is related to lower HbA1c in patients with both CAD 
and T2DM. However, the direction of this association over time is unknown. T2DM increases 
the risk for cardiac events, and it also increases the risk for long-term mortality after 
revascularization. Self-efficacy differs based on the T2DM drug therapies used (insulin versus 
oral therapy).  Self-efficacy is also greater in revascularized patients compared to patients 
without revascularization, and this difference was seen up to 12 weeks post-procedure.  
Future research must be conducted with a more demographically diverse population, 
because minorities such as Blacks and Native Americans are disproportionately affected by 
T2DM and CAD (AHA_ASA, 2007; CDC, 2005).  Larger sample sizes are also needed in order 
to increase power, thereby reducing a type II error. A prospective study design would allow for 
the analysis of causality, compared to cross-sectional studies.  Also, research on the association 
between self-efficacy and CAD/T2DM management is needed over a greater follow-up period.  
The effects of self-efficacy on cardiac morbidity and mortality in a population with both T2DM 
and CAD need to be examined given the high rate of comorbidity of the chronic conditions. 
Therefore, BARI 2D is an ideal study in which these issues can be evaluated. 
 
33 
 
 3.0  PAPER 1: SELF-EFFICACY AND RANDOMIZED TREATMENT THERAPIES FOR 
TYPE 2 DIABETES MELLITUS AND CORONARY ARTERY DISEASE 
3.1 ABSTRACT 
OBJECTIVE: The purpose of this study is to examine whether randomized treatment strategies 
for comorbid Type 2 diabetes and coronary artery disease are associated with patients’ 
confidence in being able to manage their conditions, otherwise known as self-efficacy. 
METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes 
(BARI 2D) trial, we examined 1,013 patients from the United States (US) and Canada sites. 
First, elective revascularization by either coronary artery bypass graft (CABG) or percutaneous 
coronary intervention (PCI) was selected by a physician as the more appropriate form of 
revascularization. Patients were then randomized to undergo the recommended revascularization 
immediately or to receive initial medical therapy with the option of revascularization in the event 
of worsening cardiac symptoms; patients were also randomized to glycemic therapy by either 
insulin-sensitizing drugs or insulin-providing drugs. The self-efficacy assessment from the 
Chronic Disease Self-Management Study was administered at baseline and annually throughout 
the study. In order to examine how scores could both increase and decrease, analyses were 
limited to patients whose baseline self-efficacy scores were ≤8 out of 10. Generalized estimating 
34 
 
 equations (GEE) were used to determine whether significant associations existed between self-
efficacy scores and randomized treatment therapies over time.  
RESULTS: There was an average increase in self-efficacy over time, which did not differ by 
randomized treatment. Over the course of four follow-up years, self-efficacy did not differ 
significantly between the immediate revascularization and initial medical therapy groups 
(β=0.04, p=0.65), nor between the insulin-sensitizing and insulin-providing groups (β=0.02, 
p=0.83).  
CONCLUSIONS: Self-efficacy increased over time, but was not associated with treatment 
strategies for Type 2 diabetes and cardiovascular disease. Confidence in being able to manage 
one’s disease is not hindered or enhanced by the type of therapies, despite differences in 
therapies. 
3.2 INTRODUCTION 
Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are highly comorbid 
conditions that require patients to adapt lifestyle changes and commit to self-management 
regimens. The optimal treatment strategies for these conditions have been investigated by the 
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Patients were 
randomly assigned to treatment for both T2DM and CAD; overall, there were no differences in 
survival rates and cardiovascular events between the treatment groups (BARI_2D_Study_Group, 
2009). However, in patients deemed eligible for coronary artery bypass graft (CABG), 
immediate revascularization was associated with a lower risk of major cardiovascular events 
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 compared to patients with initial treatment by medical therapy (BARI_2D_Study_Group, 2009). 
Randomization to insulin-sensitizers was associated with better glycemic control and fewer 
hypoglycemic episodes (low blood sugar) compared to insulin-providers. The effect of these 
randomized therapies for T2DM and CAD on the patients’ confidence in their ability to make the 
different types of assigned changes necessary for optimal health maintenance, also known as 
self-efficacy, has not been established. 
3.2.1 Coronary Artery Disease and Type 2 Diabetes 
Approximately 23.6 million people in the United States (US) have T2DM (17.9 million 
diagnosed and an estimated 5.7 million undiagnosed), and the lifetime prevalence is 17% 
(NIDDK, 2007). Complications from T2DM, if left untreated or poorly managed, are blindness, 
amputations, end stage renal disease, and cardiovascular complications such as myocardial 
infarction (MI [heart attack]), stroke, and death (NIDDK, 2007). Patients with diabetes have a 
two- to three-fold increased risk of coronary artery disease (CAD) compared to patients without 
diabetes, with the risk increasing over time (Kannel & McGee, 1979). In 2004, CAD was the 
leading cause of death in persons 65 years or older with T2DM, accounting for 68% of the deaths 
(NIDDK, 2007). In 2005, CAD was the leading cause of death in the US  (CDC, 2008). 
Approximately 80 million adults (approximately 1 in 3) have some form of CAD (CDC, 2008).  
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 3.2.2 Self-efficacy 
Patients with both T2DM and CAD must engage in daily regimens in order to make positive 
changes in their health and decrease their risk of disease-related morbidities. The confidence to 
successfully make these changes is called self-efficacy and is one component of Albert 
Bandura’s social learning theory (Bandura, 1977). Social learning theory postulates that people 
learn through observing other’s behaviors, personal attitudes, and outcomes of the behaviors. 
The person then decides if these behaviors should be modeled. Whether or not one decides if the 
behaviors should be and can be modeled is strongly based on confidence that once can do the 
behaviors (A. Bandura, 1977, 1982). 
3.2.3 Management 
The management of T2DM and CAD is not uniform across patients and is a multifaceted 
process. Universally, all patients must make lifestyle changes that involve diet, exercise, foot 
care, and medication adherence. The management of these comorbid diseases focuses on the 
control of HbA1c, blood pressure, and cholesterol levels. There is, however, a diverse range of 
medication and hospital interventions, each differing in patient-physician involvement, pain, 
relief of pain, and complexity. The level of difficulty involved in managing one’s health can be 
the pivotal transitioning factor that advances a person from knowing (s)he should do a behavior, 
to the assessment of his or her ability to carry out the behavior, to the execution and maintenance 
of that behavior, as described by social learning theory in its application to disease management 
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 (Albert Bandura, 1991). In addition, maintenance/adherence is influenced by both behavior 
difficulty and outcome satisfaction.  
Glycemic control within T2DM involves achieving and maintaining normal levels of 
HbA1c (<7%) with insulin-sensitizing therapy (oral), insulin-providing therapy (injectable and 
oral), or a combination therapy. Better self-efficacy enhances self-management behaviors, such 
as medication adherence, a higher frequency of blood glucose testing, and a healthy diet, that in 
turn influence glycemic control (Aljasem, et al., 2001; Chlebowy & Garvin, 2006b; R. Nakahara, 
et al., 2006; Nelson, et al., 2007; Sousa, et al., 2005). Non-adherence to oral diabetes medications 
is one of the leading factors for poor glycemic management (Guillausseau, 2003).  In one study, 
patients on oral medications had higher measures of self-efficacy regarding motivation to change 
and ability to cope with feelings than patients on insulin (Via & Salyer, 1999).  In an additional 
study, lower self-efficacy was related to the burden of injecting and adjusting insulin  (Iris 
Weijman, et al., 2005). The cross-sectional designs of most of these studies imply association, 
but cannot establish causality or direction of association.  Insulin is prescribed for more severe 
T2DM and for T2DM with a long duration; patients in the study were not randomized to the 
types of glycemic therapy (Moghissi, et al., 2009). It is still unclear whether self-efficacy differs 
by the type of glycemic therapy due to the lack of randomization of glycemic management; 
therefore, the patients may have differed clinically by the type of insulin therapy prescribed by 
their physicians prior to entering the study.   
Diabetes therapy also includes control of CAD risk factors such as high levels of low 
density lipids (>100) and hypertension (>130/80 mmHg) through medications and lifestyle 
interventions (Gavin, et al., 2003; Ripsin, et al., 2009; Wattana, et al., 2007). Treatment options 
for CAD include 1) medical management with diet, exercise, and medicine; and/or 2) 
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 revascularization either by coronary artery bypass graft (CABG) or percutaneous coronary 
intervention (PCI). Confidence in self-management may differ according to the treatment 
prescribed. Health-related quality of life and self-efficacy significantly improve after 
revascularization by CABG or PCI (Aron, et al., 2007; Gardner, et al., 2003). This improvement 
in self-efficacy persists over time. In a longitudinal study of elderly patients with MI or who had 
undergone CABG, patients who had undergone CABG during the study had greater mean self-
efficacy at week 12 compared to the MI patients (p<0.001). Mean self-efficacy expectation 
scores were moderately high post-procedure for all self-management behaviors, and the scores 
increased significantly by two weeks post-discharge. Revascularization by percutaneous 
transluminal coronary angioplasty (PTCA) and CABG increased self-efficacy over time, 
especially in patients who have received CABG with no history of MI (Perkins & Jenkins, 1998). 
These studies were limited by small sample sizes, and all White, physically mobile, and non-
randomized samples of convenience, so the clinical profile of the patients varied by treatment 
assignment. Thus, this increases the Type II error, limits their generalizability, and introduces 
selection biases.  
3.3 RATIONALE 
Diabetes therapy by use of insulin drugs and non-insulin drugs places different demands on 
patients. Insulin is primarily provided in an injectable form and is prescribed for people with 
more severe forms of T2DM and a longer duration of T2DM (Moghissi, et al., 2009). Insulin 
secretagouges (part of the insulin-providing drug class) and insulin-sensitizing drugs come in an 
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 oral form. Although the overall concept of taking one’s medications remains the same, the 
physical act of injecting insulin differs greatly from taking an oral insulin-sensitizing medication. 
Some people find that the injection of insulin is much easier than adhering to healthy dietary 
habits (I. Weijman, et al., 2005). For others, insulin injections are painful, but necessary, 
procedures. The pain and the fear of needles brings about anxiety in some patients, resulting in a 
reduction in medication adherence (Zambanini, Newson, Maisey, & Feher, 1999). Therapies 
such as these can affect one’s self-efficacy in that the patients know what they should to do 
adhere to their injections, but may not want or be able to adhere to the injections. Therefore, they 
may lack the self-confidence to carry out the behavior that they know will improve their health.  
The outcomes of management must also be considered. Within the BARI 2D trial, 
insulin-providing drugs, whether injectable or oral, have been associated with poorer glycemic 
control and increased risk factors compared to patients on insulin-sensitizing drugs 
(BARI_2D_Study_Group, 2009). Patients who were assigned to insulin-providing therapy were 
less likely to achieve the target of HbA1c <7.0%, had more hypoglycemia (low blood sugar), had 
less high density lipids (good cholesterol), and had higher body mass indexes (BMI) throughout 
the study compared to patients on insulin-sensitizing drugs (BARI_2D_Study_Group, 2009). 
Poorer performance accomplishments can affect self-efficacy by decreasing confidence in self-
management. This lack of self-confidence associated with adherence or the accomplishments 
may result in decreased health status, leading into a feedback loop (Figure 5). This widens the 
gap between the treatment’s efficacy and effectiveness, a public health problem that needs to be 
addressed. Therefore, patients in BARI 2D who are randomized to insulin-sensitizing therapy are 
hypothesized to have greater self-efficacy than patients randomized to insulin-providing therapy 
during the study. 
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 In the context of cardiology, treatments that provide immediate relief from angina, such 
as revascularization, can in turn improve one’s self-confidence in managing their conditions. 
Angina varies in severity from mild and stable to severe and unstable (Campeau, 1975). If a 
patient has a relatively severe extent of angina and is revascularized through CABG or PCI, they 
may experience immediate relief (which some may interpret as a “cure” to their CAD), which in 
turn improves their self-confidence to manage their health. Studies show that self-efficacy 
improves after revascularization and continues to improve with time (Aron, et al., 2007; Gardner, 
et al., 2003). Revascularization in BARI 2D has also been associated with a decreased risk of 
death and the composite endpoints of death/MI/ stroke among CABG patients compared to 
medical therapy (BARI_2D_Study_Group, 2009). Therefore, patients in BARI 2D who are 
randomized to immediate revascularization are hypothesized to have greater self-efficacy than 
patients randomized to immediate medical therapy during the study.  
3.4 SPECIFIC AIMS 
Using data from the BARI 2D trial, the purpose of this study was to compare self-efficacy over 
time by a diabetes treatment strategy of insulin-sensitizing drugs or insulin-providing drugs and a 
cardiac treatment strategy of initial revascularization or initial medical therapy in patients with 
comorbid T2DM and stable CAD. In order to examine change in either direction, this analysis 
will focus on patients on patients whose self-efficacy scores had the ability to decrease and 
increase over time. Among these patients, the following hypotheses were tested:  
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 1. Patients randomized to insulin-sensitizing therapy will have greater follow-up self-
efficacy than patients randomized to insulin-providing therapy.  
2. Patients randomized to immediate revascularization will have greater follow-up self-
efficacy than patients randomized to initial medical therapy. 
3. Within the revascularization strata of PCI and CABG, patients randomized to 
immediate revascularization will have greater follow-up self-efficacy than patients 
randomized to initial medical therapy. 
3.5 METHODS 
3.5.1 BARI 2D 
BARI 2D is a multicenter clinical trial designed to determine optimal treatment strategies for 
patients with T2DM and documented stable CAD. Using a 2x2 factorial design, BARI 2D 
compared initial elective revascularization with aggressive medical therapy (will be referred to as 
immediate revascularization) versus initial aggressive medical therapy and delayed 
revascularization if symptoms worsen or  are clinically indicated (will be referred to as medical 
therapy), while simultaneously studying an insulin-providing versus an insulin-sensitizing 
strategy of glycemic control to achieve a clinical target of HbA1c <7% (Figure 6) 
(BARI_2D_Study_Group, 2006). 
Randomization to either immediate revascularization or initial medical therapy was 
stratified by BARI 2D site and by intended revascularization by either PCI or CABG as 
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 determined by a physician.  Follow-up visits occurred monthly for the first six months and 
quarterly thereafter, until the end of the study in 2008. At each follow-up visit, information about 
clinical risk factors, diabetes complications, clinical events, and medications was collected.  Self-
efficacy data were collected annually as part of the quality of life assessments. The mean follow-
up per patient was 5.3 years with a range of 3.5 - 6 years. The BARI 2D primary endpoint was 
all-cause mortality. The composite secondary endpoint was death, non-fatal MI, or stroke.  
3.5.2 Population  
Participants were enrolled from 49 clinical sites in the US, Canada, Brazil, Mexico, the Czech 
Republic, and Austria (N=2,368). Eligible participants had a “diagnosis of T2DM and 
angiographically documented CAD for which revascularization was not required for prompt 
control of severe or unstable angina” (BARI_2D_Study_Group, 2006). A physician/investigator 
at each site determined if the patients were eligible for the study based on the inclusion/exclusion 
criteria. Based on the BARI 2D Manual of Operations (BARI_2D_Coordinating_Center, 2002-
2005), inclusion criteria were as follows: diagnosis of T2DM, coronary arteriogram showing one 
or more vessels amenable to revascularization (≥50% stenosis), objective documentation of 
ischemia or subjectively documented typical angina with ≥70% stenosis in at least one artery, 
suitability for coronary revascularization by at least one of the available methods, ability to 
perform all tasks related to glycemic control and risk factor management, age 25 or older, and 
informed written consent (BARI_2D_Study_Group, 2006). Exclusion criteria were as follows: 
definite need for invasive intervention as determined by a cardiologist, any CABG or PCI within 
the past 12 months, class III or IV CHF, creatinine >2.0 mg/dl., HbA1c >13%, need for major 
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 vascular surgery concomitant with revascularization (e.g., carotid endarterectomy), left main 
stenosis >50%, non-cardiac illness limiting mortality, hepatic disease, fasting triglycerides 
>1,000 mg/dl in the presence of moderate glycemic control (HbA1c ≤8.0%), current alcohol 
abuse, chronic steroid use, known/planned/suspected pregnancy, geographically inaccessible or 
unable to return for follow-up, enrolled in a competing randomized trial or clinical study, and 
unable to understand or cooperate with protocol requirements (BARI_2D_Study_Group, 2006).  
Of all the BARI 2D patients, most were White non-Hispanic males with a mean age of 
62.4±9. Of the 2,368 randomized patients, 1,499 patients were from the US sites and 353 patients 
were from the Canadian sites (Figure 7; n=1,852). Given differences in the administration of the 
self-efficacy assessment (oral versus read), the additional sites from other countries were not 
included in the analyses. Approximately 30% of all patients were racial/ethnic minorities. About 
a third of the patients (27%) came into the study on insulin. Forty-five percent of the patients had 
the combined risk factors of hypertension, hypercholesterolemia, and smoking, nearly a third had 
a history of clinically documented MI, and seven percent had a history of CHF.  Less than a 
quarter of patients had a prior revascularization. Selection of CABG over PCI as the 
revascularization method for patients was mainly based on angiographic factors, such as triple 
vessel disease (odds ratio [OR]=4.43, p<.005), left anterior stenosis ≥70% (OR=2.86, p<.005), 
and totally occluded lesions  (OR=2.35, p<.005). Patients selected for CABG were also more 
likely to be age 65 and older (OR=1.43, p<0.01) and from non-US sites (OR=2.89, p<0.01) than 
were those selected for PCI (Kim, et al., 2009).   
Because we are interested in examining how the randomized treatment is related to the 
change in self-efficacy scores, we examined patients whose baseline scores were ≤8 (n=889). 
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 The scores of these selected patients had the ability to increase and decrease over time in contrast 
to those patients with scores >8 who had limited room to increase. 
3.5.3 Data Collection and Measures 
3.5.3.1 Self-efficacy 
Study participants completed a comprehensive battery of self-reported psychosocial 
measurements including four questions regarding their self-efficacy. The self-efficacy 
assessment was administered at baseline and annually at Years 1 through 6 and was designed to 
measure how confident the patient was in his or her ability to do tasks and activities that relate to 
managing his or her T2DM and CAD in general and specific ways (Appendix A). The self-
efficacy assessment was derived from the Chronic Disease Self-Management Study and was 
found to have high internal consistency (Crohnbach’s α=0.89) (Lorig, 1996). The questions were 
modified from disease management in general to address heart disease and T2DM specifically. 
Each question consisted of a 10-point Likert scale with “1 = not at all confident” and “10 = 
totally confident.” Interest lied in the patients’ confidence in: 1) doing all day-to-day things 
necessary to manage their conditions; 2) doing activities for their T2DM and CAD in order to 
reduce doctor visits; 3) reducing emotional stress associated with their diseases through acts such 
as prayer, meditation, art, and social contact; and 4) doing activities besides medication 
adherence, such as exercise, hobbies, and dieting, to reduce the impact of the diseases on their 
daily life.  The final score was an average of the four subscale scores. 
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 3.5.3.2  Randomized Therapies 
Prior to randomization, the medical intervention by either CABG or PCI was recommended by a 
BARI 2D physician. CABG is prescribed for a more severe extent of CAD compared to PCI. 
Patients randomized to immediate revascularization received their assigned intervention by a 
BARI 2D certified technician within four weeks of randomization in addition to medical therapy. 
A proportion of patients randomized to initial medical therapy received revascularization at a 
later stage in the trial if their symptoms worsened or if there were cardiac events.  
Randomization to either insulin-sensitizing drugs or insulin-providing drugs required that 
patients adopt the assigned form of drug therapy, regardless of insulin use status at baseline. 
Patients randomized to insulin-sensitizing drug therapy were to be treated with 
thiazolidinediones or metformin, while patients assigned to insulin-providing drug therapy were 
treated with sulfonylurea, repaglinide, nateglinide, or insulin (BARI_2D_Study_Group, 2006). If 
over the course of the study, a patient’s HbA1c remained >8%, (s)he was to receive glucose-
lowering drugs from the other treatment arm. Initiation of the randomized glycemic therapy and 
additional control of HbA1c was based on an algorithm for optimal glycemic control through 
combination therapy (Magee & Isley, 2006). 
3.5.3.3 Variables of interest 
At the baseline visit, extensive clinical, demographic, and psychosocial data were collected 
including education, height, weight, HbA1c, duration of T2DM, history of MI, history of 
hypoglycemia, angina, blood pressure, lipid values, and number and type of medications. Current 
insulin use at baseline was self-reported by the patient. Duration of diabetes was measured as the 
time between diagnosis and study entry. Angina was self-reported and measured by the Canadian 
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 Cardiovascular Classification System of Angina Pectoris (CCS), which is measured on a scale 
from 1 – 4 of increasing severity as measured by activities triggering chest pain (Campeau, 
1975).  
In order to assess self-rated health, patients were asked to rate their general health as 
either “Excellent,” “Very Good,” “Good,” “Fair,” or “Poor” (Ware & Sherbourne, 1992).  Health 
distress and energy were assessed by a 9-item questionnaire in which patients reported how they 
felt during the past four weeks (Stewart & Ware, 1992). Patients were given five answer options 
which ranged from “All of the Time” to “None of the Time.” The Duke Activity Status Index 
(DASI), a 12-item questionnaire that measures the functionality of the patients in daily and 
recreational activities, was administered (Crohnbach’s α=0.67) (Dorian, et al., 2002). 
3.5.4 Statistical Methods 
The mean follow-up time for patients was 5.3 years. We limited our analyses from baseline to 
Year 4, due to the large amount of missing data at Years 5 and 6, which was attributable to the 
extended recruitment phase. In order to examine the change in self-efficacy in patients whose 
scores had the ability to both increase and decrease over time, analyses were also limited to 
patients with baseline self-efficacy scores ≤8.  
Normality of the distribution of the self-efficacy scores was assessed at baseline. Given 
the large sample size in this analysis (N=1,657), the distribution of the variance can be 
considered approximately normal (central limit theorem). There was sufficient power to detect 
small departures from normality based on skewness, kurtosis, and visual inspection.  
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 We compared the difference between the follow-up self-efficacy scores from baseline to 
Year 1, Year 1 to Year 2, Year 2 to Year 3, and Year 3 to Year 4. The self-efficacy score is the 
mean of four 10-point subscales. A difference of 0.5, which is based on the effect size seen in the 
literature that produced a significant difference in self-efficacy scores between diabetes treatment 
types, was defined as a meaningful change (Via & Salyer, 1999). A difference of ≥0.5 points 
indicates that at least half of the subscales have either increased or decreased in the same 
direction by one point. Minimal change was defined as <0.5 difference in follow-up self-efficacy 
score compared to the baseline score. A decrease or increase was defined as a 0.5-1.5 difference 
from the baseline score. A large increase and a large decrease were defined as a >1.5 point 
change from baseline (>1 standard deviation [sd]).  
Using intention-to-treat analyses, we analyzed self-efficacy by comparing the following 
categories of randomized treatment: glycemic therapy (insulin sensitizers versus insulin 
providers); cardiovascular management (initial revascularization versus initial medical therapy); 
and cardiovascular management within the intended cardiac revascularization stratum (CABG 
and PCI). Wilcoxon signed-rank tests were used to compare the mean self-efficacy scores 
between treatment groups at baseline. Generalized estimating equations (GEE) models were 
constructed to test the significance of the mean change in self-efficacy scores over time, with all 
self-efficacy scores included as dependent variables and years in study (including baseline) as 
the independent variable, controlling for within subject correlation. 
In order to estimate the effect of the randomized treatment groups on self-efficacy scores 
over time, GEE models were constructed. The dependent variable was the follow-up self-
efficacy score and the independent variable was the randomized treatment group. Each GEE 
model controlled for baseline self-efficacy scores, randomized cardiac or glycemic therapy, 
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 follow-up years, and within subject correlation. Time in the study was used as a repeated 
measure (follow-up years) and as an interaction term with the randomized treatment of interest to 
measure change from baseline. Separate models were created to examine the effect of 
randomized cardiac therapy within the revascularization strata (CABG and PCI) stratum. 
Because patients were required to adopt the randomized form of glycemic therapy despite their 
current form of therapy upon study entry, separate models were created to examine the effect of 
randomized diabetes therapy within patients based on baseline insulin use (no or yes). 
In the GEE models, the coefficients for the treatment variables represent the estimated 
difference in self-efficacy for the revascularization group versus the medical therapy group 
(Models 1-3) and the insulin-sensitizing group versus the insulin providing group (Models 4-6). 
The coefficients for the time variables show the estimated difference in self-efficacy for each 
time point compared to Year 4. The coefficients for the treatment*time interaction estimate the 
difference for each year between the treatment groups. The overall p-values for time and 
treatment*time interaction test the hypothesis that at least one of the coefficients is equal to zero. 
For the patients randomized to revascularization, the difference in self-efficacy compared to 
Year 4 patients randomized to medical therapy is the addition of the coefficients for treatment 
and treatment*time interaction. Likewise, for the patients on insulin sensitizers, the difference in 
self-efficacy compared to the Year 4 patients on insulin providers is the addition of the 
coefficients for treatment and treatment*time interaction. 
We expected to see a moderate effect size of approximately 0.5 between treatment 
groups. Using a sample size analysis based on t-tests, there was >0.84 power (two-sided α=0.05) 
to detect a 0.4 difference for a small effect size and a 0.6 difference for a large effect size 
between comparison groups at all time points. After adjusting for multiple comparisons 
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 (Bonferroni α=0.01), there was >0.64 power to detect a 0.4 difference and >0.97 power to detect 
a 0.6 difference. All analyses were performed using SAS version 9.2; all power analyses were 
conducted using SAS Power and Sample Size 3.1 (SAS Institute Inc., Cary, NC, 2007). 
3.6 RESULTS 
In the US and Canadian sites, 1,657 had a baseline self-efficacy score and at least one follow-up 
score. The baseline self-efficacy score was 7.72±1.81, median=8.0, skewness=-0.85 and 
kurtosis=0.54 (Figure 8). The characteristics of these patients at study entry are shown in the 
first column of Table 4. At study entry, patients were predominately male (71.8%), with an 
average age of 62.6±8.9 years. The patients were racially and ethnically diverse, with 64.5% 
White non-Hispanic, 18.3% Black non-Hispanic, 11.5% Hispanic, and 5.7% Other non-Hispanic 
(including Asian and Native American) patients. The majority of the patients had a high school 
education and above. There were few smokers (12.9%) and patients with a history of cancer 
(9.1%).  The average duration of diabetes in the BARI 2D patients was 10.6±8.8 years. Patients 
had a mean HbA1c of 7.5% ±1.5% and probable neuropathy was screened in 15.6% of patients.  
About a third of patients were using insulin at the time of randomization and the average number 
of hypertension drugs was 2.3±1.  A low percentage of patients (7.4%) had a history of 
congestive heart failure and a third had a history of MI (28.2%). A large proportion of patients 
had a clinical history of hypertension and hypercholesterolemia requiring treatment. Just over 
half of patients reported angina symptoms. Mean systolic blood pressure was 130.7±18.5 mmHg 
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 and the median LDL was 90 mg/dl. The mean self-efficacy score was 7.7±1.8. More than half of 
the patients rated their health as “Good” to “Excellent” (Table 5).  The patients rated their 
energy and their ability to carry out daily activities as low (DASI). Baseline self-efficacy scores 
were balanced between randomized treatment groups. 
Examining only patients whose baseline scores were ≤8, there were 889 patients at 
baseline, 873 at Year 1, 827 at Year 2, 788 at Year 3, and 711 at Year 4. The reasons for lost to 
follow-up are listed in Appendix B. The total numbers of events are not mutually exclusive, so 
one patient may have several of the listed events. For Years 1 -3, most patients were lost to 
follow-up due to rescission of consent and death. Towards the end of the study, most patients 
were lost due to death and study close-out. Time in the study was positively associated with self-
efficacy scores overall (β=0.19, p<.001; Figure 9). The self-efficacy scores increased 
significantly from baseline to Year 4 (p<.001; Figure 10 Figure 11). However, there were no 
significant differences between the randomized therapies overall and within either of the 
treatment strata. 
 Table 6 shows the mean scores and standard deviation per follow-up period by treatment 
assignment and strata for those patients with baselines scores ≤8. Although the medical group 
and the insulin-providing group had lower self-efficacy scores compared to the revascularization 
group and the insulin-sensitizing group respectively, none of the treatment comparisons were 
significantly different. The mean self-efficacy scores increased over the years within each of the 
treatment arms (p-values ≤0.05). 
The adjusted GEE models 1 – 3 were created to compare improvement in self-efficacy 
between patients assigned to revascularization versus medical therapy, overall and within 
designated patient subgroups (Table 7). Self-efficacy scores of patients randomized to initial 
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 revascularization did not significantly differ from scores of patients randomized to medical 
therapy overall and within revascularization strata. Time was significant overall (p=0.002) and 
within the PCI stratum (p<.001). The time*treatment interactions were not significant. 
The adjusted GEE models 4 - 6 were created to compare improvement in self-efficacy 
between patients assigned to insulin-sensitizing to insulin-providing treatments (Table 8). 
Patients randomized to insulin-sensitizers did not differ in self-efficacy from those randomized to 
insulin-providers overall or by insulin use at baseline.  Time was significant overall and within 
patients with no baseline insulin use. Self-efficacy at Year 1 was significantly lower than Year 4 
overall and within patients with no insulin use at baseline. The time*treatment interactions were 
not significant. 
The interactions between treatment and time did not reach statistical significance in any 
of the models, and thus were removed when assessing the main effect of treatment assignment 
(Table 9). There were no significant differences in self-efficacy scores between revascularization 
versus medical therapy (β=0.03, p=0.76) overall and within the CABG and PCI strata. 
Additionally, there were no significant differences between insulin sensitizers versus insulin 
providers (β=0.02, p=0.79) overall and within patients with and without insulin use at baseline.   
3.7 DISCUSSION 
For those patients with CAD and T2DM who have self-efficacy scores ≤8, there were no 
differences in follow-up self-efficacy scores based on randomization to treatment with insulin-
sensitizing drugs versus insulin-providing drugs, or in randomized treatment to early 
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 revascularization compared to initial medical therapy.  Similar to results by Perkins et al. (1989), 
this study showed that over time, self-efficacy increased or remained stable.  
CABG is prescribed for more severe CAD compared to PCI, and immediate 
revascularization by CABG has been shown to decrease the rates of the clinical endpoints (death 
and a composite of death/MI/stroke) in BARI 2D patients (BARI_2D_Study_Group, 2009; Kim, 
et al., 2009). Given that self-efficacy is also associated with better clinical outcomes, we 
hypothesized that better self-efficacy would be observed in the revascularization group compared 
to the medical group within patients (Sarkar, Ali, & Whooley, 2009). This would be particularly 
noticeable in patients with more severe CAD. However, in patients for whom CABG was 
deemed the appropriate form of revascularization, our study showed there was no difference in 
self-efficacy between the cardiac therapies.  
Insulin use at baseline is indicative of a more severe extent of T2DM and poor glycemic 
control (Moghissi, et al., 2009). Since insulin use is a marker for more advanced T2DM, it is 
difficult to distinguish in cross-sectional studies whether the insulin effect is due to treatment or 
due to the disease. Our study indicates that it is not due to treatment. There was no association 
between self-efficacy scores and randomization to insulin-sensitizing or insulin-providing 
therapy overall or by insulin use at baseline. These results are counter to the results of Via and 
Salyer (1999), whose results showed that patients on oral medication had higher self-efficacy 
than those on injectable insulin. These null results may reflect drug therapy cross-over and 
combination drug therapy of insulin-sensitizing and insulin-providing therapy. In addition, 
insulin-providing drugs are not solely injectable as the insulin secretagouges come in oral form.  
Patients whose baseline self-efficacy scores were ≤8 showed an increase in self-efficacy 
scores over time. With its aggressive medical therapy either via drug therapy, coordinated care, 
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 and/or revascularization, participation in BARI 2D, regardless of treatment type, may have 
increased the patient’s confidence in being able to manage their conditions and provided a sense 
of empowerment. In BARI 2D, patients have regular contact with health care professionals, 
including dedicated nurses.  
A large clinical trial such as BARI 2D has multiple advantages in studying self-efficacy 
in patients with comorbid CAD and T2DM. One of the major strengths of the study was the 
randomization of treatment therapies. This ensured that the patients were demographically and 
clinically similar between the treatment groups.  The patients in the study were demographically 
diverse, so that the results are generalizable to patients of various races, ethnic groups, education 
levels, and sexes. The large sample size gave us sufficient power to detect at least a moderate 
effect size at all time points. BARI 2D also has an extensive database of clinical measures 
relating to T2DM and CAD so that clinical factors associated with self-efficacy can be studied. 
In this analysis, self-efficacy improved significantly over time in patients with treatments 
associated with less severe extent of CAD and T2DM. By Year 4, self-efficacy was higher than it 
was at Year 1 for patients within the PCI stratum and who had no insulin use at baseline. Future 
analyses will further investigate the relationship between the clinical measures that are associated 
with self-efficacy.   
There are several limitations that need to be addressed in future analyses. Because the 
focus of this paper is randomized treatment for T2DM and CAD, the intention-to-treat analyses 
did not account for the treatment received. Within the first 6 months of study entry, 95% of the 
initial revascularization group received revascularization and 13% of the medical therapy group 
received revascularization; by Year 3, 33% of the medical patients had undergone 
revascularization as clinically indicated (BARI_2D_Study_Group, 2009). Patients whose HbA1c 
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 was not properly managed by their randomized drug therapy (HbA1c ≥8%) crossed over to the 
other therapy or received combination therapy. By Year 3, nearly 90% of patients were on the 
assigned diabetes therapy; 43% of the insulin-sensitizing group and 12% of the insulin-providing 
group received additional medication from the alternative drug class to assist in glycemic control 
(BARI_2D_Study_Group, 2009). Future analyses will control for the cross-over rates in diabetes 
therapy and the form of insulin therapy.  
In summary, confidence in being able to manage one’s disease is not hindered or 
enhanced by the type of therapies, despite their differences. Self-efficacy was found to increase 
over time in patients whose self-efficacy was moderately good and who were participating in a 
medically aggressive program of health care. Clinical measurements, such as HbA1c, lipids, and 
blood pressure, that are dependent on the type of treatment, must be considered when examining 
self-efficacy in patients with CAD and T2DM.  
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3.8 TABLES AND FIGURES FOR PAPER 1 
Table 4. Demographics and baseline clinical status by baseline self-efficacy scores 
Characteristic Total (N=1,657) 
Baseline SE Score ≤8 
 (N=889) 
Baseline SE Score >8 
 (N=768) p-value 
Male, % 71.8 69.9 74.1 0.06 
Age at study entry, mean, SD 62.6, 8.9 62.4, 8.9 62.8, 8.9 0.46 
Race/Ethnicity, %     
  White nH 64.5 60.5 69.0 <.0001 
  Black nH 18.3 18.3 18.4  
  Hispanic 11.5 15.1 7.4  
  Other nH 5.7 6.1 5.2  
Education, %     
  Some high school or less 25.3 28.6 21.6 <.0001 
  High school diploma 25.8 28.2 23.0  
  Post high school education 28.9 27.9 30.1  
  Bachelors Degree or higher 19.9 15.3 25.3  
United States Site, % 79.5 78.6 80.6 0.32 
Current use of cigarettes or other tobacco 
product, % 12.9 15.9 9.5 0.00 
Malignancy, % 9.1 8.5 9.8 0.39 
HbA1c %, mean, SD 7.5, 1.5 7.6, 1.6 7.4, 1.5 0.00 
HbA1c ≥8%, % 30.9 33.7 27.6 0.01 
Probable neuropathy: screening MNSI  ≥7, % 15.6 20.2 10.3 <.0001 
Currently taking insulin, % 29.8 34.4 24.5 <.0001 
Duration of diabetes (years), mean, SD 10.6, 8.8 11.3, 8.9 9.9, 8.6 0.00 
Angina category, %     
  No angina 43.2 40.2 46.7 0.02 
  Angina CCS 1, 2 39.6 41.4 37.6  
  Angina CCS 3, 4 or unstable 17.1 18.4 15.6  
History of treated congestive heart failure, % 7.4 9.3 5.2 0.00 
History of myocardial infarction, % 28.2 28.7 27.7 0.67 
Number of hypertension drugs, mean, SD 2.3, 1.0 2.4, 1.0 2.2, 1.0 <.0001 
Hypercholesterolemia requiring treatment, % 82.9 85.3 80.1 0.01 
Sitting systolic blood pressure (mmHg), mean, 
SD 130.7, 18.5 131.4, 19.0 129.9, 17.9 0.11 
Systolic blood pressure >140 mmHg, % 25.1 25.9 24.2 0.44 
Low density lipids mg/dl, median (interquartile 
range) 90 (72-112) 91 (72-113) 88 (72-112) 0.16 
Low density lipids ≥ 100 mg/dl, % 35.1 36.2 33.7 0.29 
     
 Table 5. Baseline quality of life measures and randomized treatment and strata by baseline 
self-efficacy scores 
Characteristic Total (N=1,657) 
Baseline SE Score ≤8 
 (N=889) 
Baseline SE Score >8 
 (N=768) p-value 
QUALITY OF LIFE     
Self efficacy score (0-10), mean, SD 7.7, 1.8 6.4, 1.5 9.3, 0.6 <.0001 
Self rated health category (1-Excellent 5 - 
Poor), %     
  Excellent 1.6 0.4 2.9 <.0001 
  Very good 10.7 5.3 16.9  
  Good 41.5 35.0 49.1  
  Fair 33.7 41.1 25.1  
  Poor 12.6 18.2 6.0  
Duke Activity Status Index (DASI)  (0-58.2), 
mean, SD 19.8, 14.2 15.6, 12.4 24.6, 14.7 <.001 
Energy score (0-100), mean, SD 47.3, 21.5 41.4, 19.9 54.3, 21.3 <.001 
Health distress score (0-100), mean, SD 43.0, 25.3 50.7, 23.7 34.1, 24.1 <.001 
RANDOMIZED TREATMENT AND 
STRATA     
Glycemic treatment, %     
  Insulin sensitizing 50.0 48.8 51.3 0.32 
  Insulin providing 50.0 51.2 48.7  
Cardiovascular treatment, %     
  Medical therapy 51.2 52.4 49.7 0.28 
  Initial revascularization 48.8 47.6 50.3  
Cardiac revascularization strata, %     
  CABG 24.3 24.3 24.4 0.98 
  PCI 75.7 75.7 75.6  
 
Key: CABG – coronary artery bypass graft, CCS 1–CCS 4 - Cardiovascular Classification System 1 - 4, CHF – congestive heart 
failure, HbA1c – glycosylated hemoglobin, HS – high school, LDL – low density lipids, MI – myocardial infarction, nH – non-
Hispanic, PCI – percutaneous coronary intervention, SD – standard deviation 
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 Table 6. Self-efficacy scores (mean, SD) by randomized treatment assignment over time 
among patients with baseline scores ≤8  
Time N All IP IS 
Treatment  
p-value 
Baseline 889 6.4, 1.5 6.4, 1.4 6.5, 1.5 0.36 
Year 1 873 6.9, 1.9 6.9, 1.8 6.9, 1.9 0.79 
Year 2 827 7.0, 1.8 7.0, 1.9 7.1, 1.8 1.00 
Year 3 788 7.2, 1.8 7.1, 1.9 7.2, 1.7 0.51 
Year 4 711 7.2, 1.8 7.1, 1.8 7.2, 1.8 0.54 
Glycemic Therapy 
Time p-value  <.001 <.001 <.001  
Time N All REV MED 
Treatment  
p-value 
Baseline 889 6.4, 1.5 6.4, 1.4 6.4, 1.5 0.88 
Year 1 873 6.9, 1.9 6.9, 1.9 6.9, 1.9 0.65 
Year 2 827 7.0, 1.8 7.1, 1.8 7.0, 1.8 0.38 
Year 3 788 7.2, 1.8 7.2, 1.9 7.1, 1.8 0.36 
Year 4 711 7.2, 1.8 7.2, 1.8 7.2, 1.8 0.82 
Cardiac Therapy: All 
Time p-value  <.001 <.001 <.001  
Cardiac Therapy:  Baseline 216 6.6, 1.3 6.7, 1.3 6.5, 1.4 0.12 
CABG Stratum Year 1 212 7.2, 1.9 7.2, 2.0 7.1, 1.9 0.76 
 Year 2 202 7.2, 1.8 7.2, 1.6 7.2, 1.9 0.74 
 Year 3 193 7.3, 1.8 7.3, 1.7 7.3, 1.9 0.89 
 Year 4 179 7.2, 1.7 7.4, 1.7 7.0, 1.7 0.14 
 Time p-value  <.001 0.02 <.001  
Cardiac Therapy: Baseline 673 6.4, 1.5 6.3, 1.5 6.4, 1.5 0.28 
PCI Stratum Year 1 661 6.8, 1.9 6.7, 1.9 6.9, 1.8 0.42 
   Year 2 625 7.0, 1.8 7.1, 1.9 6.9, 1.8 0.26 
 Year 3 595 7.1, 1.9 7.2, 2.0 7.1, 1.8 0.30 
 Year 4 532 7.2, 1.8 7.1, 1.9 7.2, 1.8 0.55 
 Time p-value  <.001 <.001 <.001  
Key: IP – insulin-providing therapy, IS – insulin-sensitizing therapy, MED – initial medical therapy with delayed 
revascularization, REV – initial revascularization with medical therapy 
Analysis is limited to patients with baseline scores ≤8. 
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 Table 7. Separate GEE models of treatment, time, and treatment* time interaction on self-
efficacy scores  
Revascularization vs. medical 
therapy 
Follow-up 
Years 
Coefficient 
Estimate 
Standard 
Error p-value 
Overall      
p-value 
MODEL 1: OVERALL (N=889) 
Treatment  0.06 0.13 0.66   
Time 1 -0.18 0.10 0.08 0.002 
  2 -0.13 0.10 0.19   
  3 0.02 0.10 0.87   
  4 ref=0     
Treatment * Time 1 -0.13 0.15 0.39 0.67 
  2 0.04 0.14 0.76   
  3 0.00 0.14 0.99   
  4 ref=0       
MODEL 2: CABG (N=216) 
Treatment  0.32 0.25 0.20   
Time 1 0.18 0.19 0.34 0.85 
  2 0.17 0.20 0.41   
  3 0.26 0.19 0.17   
  4 ref=0     
Treatment*Time 1 -0.33 0.27 0.23 0.55 
  2 -0.30 0.29 0.30   
  3 -0.31 0.27 0.25   
  4 ref=0     
MODEL 3: PCI (N=673) 
Treatment  -0.03 0.16 0.85   
Time 1 -0.30 0.12 0.01 <.001 
  2 -0.22 0.11 0.05   
  3 -0.06 0.11 0.57   
  4 ref=0     
Treatment * Time 1 -0.06 0.18 0.73 0.50 
  2 0.16 0.17 0.33   
  3 0.11 0.16 0.52   
  4 ref=0       
 
Each model is adjusted for baseline self-efficacy score, randomized diabetes therapy, follow-up years, and the 
interaction between randomized cardiac therapy and follow-up years.  
Analysis is limited to patients with baseline scores ≤8. 
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 Table 8. Separate GEE models of treatment, time, and treatment* time interaction on self-
efficacy scores  
 
Insulin sensitizers vs. 
insulin providers Follow-up Years 
Coefficient 
Estimate Standard Error p-value 
Overall       
p-value 
MODEL 4: OVERALL (N=889) 
Treatment  0.06 0.13 0.65   
Time 1 -0.30 0.11 0.01 0.002 
  2 -0.12 0.10 0.24   
  3 0.03 0.10 0.73   
Treatment * Time 4 ref=0     
  1 -0.11 0.15 0.46 0.78 
  2 -0.02 0.14 0.88   
  3 0.04 0.14 0.79   
  4 ref=0       
MODEL 5: NO BASELINE INSULIN USE (N=583) 
Treatment  0.05 0.16 0.75   
Time  1 -0.34 0.13 0.01 0.001 
  2 -0.11 0.12 0.34   
  3 0.11 0.11 0.31   
  4 ref=0     
Treatment*Time 1 -0.16 0.18 0.37 0.58 
  2 -0.11 0.17 0.51   
  3 0.05 0.16 0.76   
  4 ref=0     
MODEL 6: BASELINE INSULIN USE (N=306) 
Treatment  0.04 0.25 0.86   
Time 1 -0.19 0.20 0.35 0.45 
  2 -0.14 0.20 0.50   
  3 -0.17 0.20 0.41   
  4 ref=0     
Treatment*Time 1 0.01 0.27 0.97 0.90 
  2 0.13 0.27 0.62   
  3 -0.05 0.27 0.86   
  4 ref=0       
 
Each model is adjusted for baseline self-efficacy score, randomized cardiac therapy, follow-up years, and the 
interaction between randomized diabetes therapy and follow-up years. 
Analysis is limited to patients with baseline scores ≤8. 
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 Table 9. Separate GEE models with randomized treatment as the main effect on self-
efficacy  
 
Treatment Groups (Main effect) Estimate Standard Error P-value 
 
Revascularization vs. medical therapy 
Model 1: Overall (N=889) 0.03 0.09 0.76 
Model 2: CABG (n=216) 0.07 0.19 0.72 
Model 3: PCI (n=673) 0.01 0.10 0.95 
 
Insulin sensitizers vs. insulin providers 
Model 4: Overall (n=889) 0.02 0.09 0.79 
Model 5: No baseline insulin use (n=583) -0.02 0.11 0.88 
Model 6: Baseline insulin use (n=306) 0.08 0.17 0.65 
 
Models 1-3 are adjusted for baseline self-efficacy score, randomized diabetes therapy, and follow-up years. 
Models 4-6 are adjusted for baseline self-efficacy score, randomized cardiac therapy, and follow-up years. 
Analysis is limited to patients with baseline scores ≤8. 
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PERSON BEHAVIOR OUTCOME 
Efficacy Expectations 
- Performance accomplishments 
- Vicarious experience 
- Verbal persuasion 
- Emotional arousal 
Outcome Expectations 
Figure 5. Author’s schematic diagram based on Bandura’s conceptual model of self-
efficacy (A. Bandura, 1977) 
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Key: IP – insulin providing, IS, insulin sensitizing, MED – medical therapy, REV – immediate revascularization 
Figure 6 BARI 2D enrollment and randomization. 
63 
 
  
 
 
 
 
 
  
 
Figure 7. Population flowchart for Aim 1 
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Figure 8. Histograms of baseline self-efficacy scores 
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β=0.19, p<.001 
 
Figure 9. Boxplots of efficacy scores and years within patients whose baseline scores ≤8 
with line connecting mean values 
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Key: IP – insulin providers, IS – insulin sensitizers, MED – medical therapy, REV - revascularization 
 
Figure 10. Mean self efficacy score over time by randomized treatment and baseline self-
efficacy score 
  
 
 
 
Key: CABG – coronary artery bypass graft, PCI – percutaneous coronary intervention, MED – medical therapy, 
REV – revascularization 
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Figure 11. Mean self efficacy score over time by randomized treatment and baseline self-
efficacy score within revascularization strata 
 
 4.0  PAPER 2: THE RELATIONSHIP BETWEEN SELF-EFFICACY AND RISK FACTOR 
CONTROL OVER TIME AND THE MODERATING EFFECT OF RACE/ETHNICITY 
4.1 ABSTRACT 
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OBJECTIVE: The purpose of this study was to examine the temporal relationship between self-
efficacy and risk factors of HbA1c, body mass index (BMI), and physical functioning over time 
in patients with comorbid Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). 
The secondary aim was to examine race/ethnicity as an effect modifier. 
METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes 
(BARI 2D) trial, we examined 1,562 patients from the United States (US) and Canada sites. 
Patients were randomized to receive treatment for both T2DM (insulin sensitizing drugs vs. 
insulin providing drugs) and CAD (immediate revascularization vs. medical therapy).  The self-
efficacy assessment from the Chronic Disease Self-Management Study was administered at 
baseline and annually throughout the study. Subject-specific mixed models and year lag models 
were used to assess the relationship between self-efficacy and the risk factors over time. 
RESULTS: Higher self-efficacy at study entry was significantly associated with greater 
reductions in HbA1c (β=-0.03, p<.001) and larger improvements in physical function during the 
trial, although the magnitude of the association between baseline self-efficacy and physical 
function declined over time (interaction p=0.02). These associations did not depend on 
 
 race/ethnicity. A feedback loop was shown between self-efficacy and all three risk factors over 
time.  The feedback association between HbA1c and self-efficacy was stronger for Whites than 
for Blacks and Hispanics.  
CONCLUSIONS: Better self-efficacy was related to improved glycemic control and physical 
functioning. Furthermore, self-efficacy was positively associated with control of risk factors up 
to the following year; and risk factor control was predictive of self-efficacy in the following year. 
This is of public health relevance because it shows how self-efficacy can be used as a marker of 
past health and a predictor of future health.  
70 
 
  
4.2 INTRODUCTION 
Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are highly comorbid 
conditions that share the same modifiable risk factors, such as being overweight and having a 
low level of physical activity.  The ability to manage health risk factors is thought to be 
influenced by the patients’ confidence in their ability to manage their conditions  (Lorig, 1996). 
Self-efficacy, the belief that one is able to make changes necessary for self-management, has 
been found to be associated with glycemic control and cardiac symptom burden (A. Bandura, 
1977; Chlebowy & Garvin, 2006b; Sarkar, Ali, & Whooley, 2007; Sullivan, et al., 1996). In 
addition, it is well documented that cardiac risk factors and glycemic control are less well 
managed in racial/ethnic minority populations, such as Blacks, Hispanics, and Native Americans, 
compared to Whites (Abate & Chandalia, 2003; AHA, 2009a; Colleran, Richards, & Shafer, 
2007). The disparities within these racial/ethnic groups also apply to self-efficacy related to 
medical management, as racial ethnic minorities report feeling less confident in being able to 
carry out the necessary behaviors for proper health care (Duru, et al., 2009). Therefore, using 
data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, 
we sought to examine the association between self-efficacy and cardiovascular and diabetes risk 
factor control over time, and how race/ethnicity modifies this association. First, we will examine 
the epidemiology of CAD and T2DM. Then we will examine self-efficacy and how it relates to 
clinical and physical risk factors, namely HbA1c, physical functioning, and body mass index 
(BMI 
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 4.2.1 Type 2 diabetes mellitus 
Racial/ethnic minorities are 1.5 to 20 times more likely to develop T2DM than their White non-
Hispanic (nH) counterparts, with prevalence rates of 6.6% in White nHs, 7.5% in Asian 
Americans, 11.8% in Black nHs, and 10.4% in Hispanics  (ADA, 2007). Based on 20 years of 
surveillance data, the Framingham Heart Study found that patients with diabetes had a two- to 
three-fold increased risk of CAD compared to patients without diabetes (Kannel & McGee, 
1979).  
Modifiable risk factors include being overweight (BMI≥25), having a sedentary lifestyle, 
and poor diet (ADA, 2009). Non-modifiable risk factors for T2DM include having a family 
history of diabetes, being of racial/ethnic minority status, and older age (ADA, 2004, 2009; 
Engelgau, et al., 2004). Minorities present worse diabetes control, receive different treatment 
regimens, are more likely to receive insulin, and have higher rates of complications (HHS, 2001). 
4.2.2 Cardiovascular disease 
Approximately 80 million adults in America (approximately 1 in 3) have some form of CAD. 
Blacks and Hispanics have higher rates of CAD compared to Whites, and the prevalence rate of 
Hispanics is 25% higher than that of Blacks (AHA, 2009a).  CAD was the leading cause of death 
in 2005, accounting for 36.2% of deaths in White nH, 33.6% in Black nH, and 39.6% in 
Hispanics (CDC, 2008).   
Modifiable risk factors are smoking/smoke exposure, high cholesterol, T2DM, sedentary 
lifestyle, high body mass index, unhealthy diet, hypertension, and alcohol consumption (AHA, 
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 2009b). Non-modifiable risk factors for CAD include being of racial/ethnic minority status, male 
sex, older age, and having a family history of CAD (especially before the age of 60). In 2010, the 
American Heart Association (AHA) added psychosocial indices to the list of risk factors as listed 
by the INTERHEART study (AHA, 2009b).  
4.2.3 Self-efficacy  
4.2.3.1 Self-efficacy and HbA1c 
Glycemic control is key in maintaining healthy levels of glucose in the blood, thereby reducing 
the risk of cardiovascular and diabetes complications (ADA, 2009). The literature presents mixed 
results regarding the relationship between glycemic control and self-efficacy, with some studies 
documenting no association and others showing a strong association. Duru et al. (2009) used a 
case-control design to examine how the associations between depression, self-efficacy, and 
medication adherence and modifiable risk factors (HbA1c, LDL, and systolic blood pressure) 
differed between Black and White patients (n=764). Cases were patients with poor control of two 
of the three measures, as measured by HbA1c ≥8.0%, LDL ≥100, and systolic blood pressure 
>130 mmHg. Controls were patients whose three measures were in good control. Self-efficacy 
was measured by two questions assessing the patients’ acknowledgement of risk and their belief 
in their ability to lower risk. The association between self-efficacy and good risk factor control 
was not significant in either race. However, depression and low medication adherence increased 
the odds of poor risk factor control in Black patients (Duru, et al., 2009).   
A study by Chlebowy and Garvin (2006) utilized a two-group comparative descriptive 
design to examine the relationships between social support, self-efficacy, and outcome 
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 expectations to T2DM self-care behaviors and glycemic control in White and Black participants 
(N=91). Self-efficacy was measured by the Self-Efficacy Questionnaire (α coefficient for overall 
score=0.92) (Chlebowy & Garvin, 2006c). Self-efficacy was not significantly related to glycemic 
control for either race, while higher outcome expectation was significantly related to better 
glycemic control in both races.  
Sarkar et al. (2006) examined the relationship between self-efficacy and T2DM 
management in a racially diverse, low-income population of 408 participants with limited ability 
to read and comprehend written health materials (poor health literacy). Self-efficacy was 
significantly associated with diet, exercise, self-monitoring of blood glucose, and foot care, even 
after controlling for T2DM factors, race, and health literacy. In an additional study, Sarkar et al. 
(2007) showed that the associations between self-efficacy and self-management (exercise, blood 
glucose monitoring, and foot care) were consistent within White, Black, Latino, and Asian 
/Pacific Islander patients. 
There are several issues one must consider when examining self-efficacy and glycemic 
control as measured by HbA1c. One, although different assessments of self-efficacy were used in 
each study, results tended to show that self-efficacy was positively associated with behaviors 
related to glycemic management.  Two, glycemic management may be based on the participant’s 
exposure to T2DM education. Patients with T2DM education may be more likely to perform the 
needed daily tasks regarding health maintenance, and they may also be of higher socioeconomic 
status, thereby having a more positive T2DM profile (Chlebowy & Garvin, 2006a). Additionally, 
few studies have reported their patient’s cardiac status. Patients with a comorbid cardiac 
condition have poorer self-efficacy than those without (Deaton, et al., 2006). Three, given the 
disparities in the control of risk factors between racial/ethnic minority groups, self-efficacy and 
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 its relation to risk factor control needs to be studied in a setting where treatment is randomized, 
thereby eliminating the differences in treatment due to race/ethnicity.  
4.2.3.2 Self-efficacy and physical functioning 
There is evidence for a positive relationship between self-efficacy and physical functioning. Self-
efficacy has been shown to be associated with physical functioning in patients with CAD. A 
study by Sullivan et al. (1998) prospectively examined the role of self-efficacy in patients with 
CAD (N=198), controlling for anxiety and depression. Like the BARI 2D study (Brooks et al., 
2006), patients were eligible for elective surgery. Instruments used were the 13-item Cardiac 
Self-Efficacy Scale, which looked at function, maintenance, and symptom control, the SF-36 
(physical functioning), and the Sheehan Family/Home and Social Interface Scales (Sheehan, 
Harnett-Sheehan, & Raj, 1996; Sullivan MD. Andrea Z, 1998; Ware & Sherbourne, 1992). Self-
efficacy was found to be a good predictor of physical function and role function after controlling 
for CAD severity, anxiety, and depression.  This study is limited in that the validity of the self-
efficacy assessment scale used has not been determined. 
The goal of a study by Sarkar et al. (2007) was to examine the relationship between 
cardiac self-efficacy and health status in 1,024 patients with congestive heart disease in the Heart 
and Soul Study, controlling for severity of congestive heart disease and depression. Cardiac self-
efficacy was measured using Sullivan’s 5-item scale (Crohnbach’s α = 0.80) (Sullivan et al., 
1998). Lower self-efficacy was found to be independently associated with greater cardiac 
symptom burden, greater physical limitations, worse quality of life, and worse overall health. 
Because the study was cross-sectional, directionality and causality cannot be established. 
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 Furthermore, the majority of the patients were older, low-income White males, limiting the 
generalizability of the results. 
In a longitudinal study of a Turkish cohort, 60 cardiac patients were randomized to a 
home-based cardiac exercise program (grounded in the theory of self-efficacy) or no intervention 
(control) in order to study each group’s lipids, exercise tolerance, and self-efficacy (Senuzun, 
Fadiloglu, Burke, & Payzin, 2006).  Self-efficacy was measured by the Cardiac Self-Efficacy 
Index (CESEI), whose test-retest reliability was 0.97 (Crohnbach’s α=0.87) (Hickey, Owen, & 
Froman, 1992). At the end of the 12 weeks, the home-based cardiac exercise group’s clinical risk 
factor profile significantly improved in comparison to the control group. Senuzun et al. (2006) 
concluded that exercise along with enhanced self-efficacy might have improved the patients’ 
exercise capacity, thereby improving their clinical outcomes. However, this conclusion may be 
premature because the control group should have an intervention that was not grounded in the 
self-efficacy theory. 
4.2.3.3 Self-efficacy and weight  
Sol et al. (2006) studied the effects of baseline self-efficacy on vascular risk factors, including 
physical activity, BMI and glucose levels in patients at high risk for developing additional 
vascular complications (Sol, van der Graaf, van der Bijl, Goessens, & Visseren, 2006). In a 
randomized trial of 153 patients with vascular disease, patients were randomized to receive either 
usual care or nursing care with self-efficacy promotion and medical therapy for one year. Self-
efficacy was measured by the adapted Type 2 Diabetes Mellitus Self-efficacy Scale 
(Crohnbach’s α=0.69) (Bijl, Poelgeest-Eeltink, & Shortridge-Baggett, 1999). Baseline and 
composite self-efficacy were related to dietary choices and an increase in physical activity, but 
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 were not related to changes in BMI or other vascular risk factors. However, BMI was related to 
self-efficacy in a study that examined the mediating effects of adherence, BMI, and self-efficacy 
in the relationship between depression and worsening T2DM (Sacco, et al., 2005). Adherence 
and BMI were independent mediators of self-efficacy and T2DM control.   
In a sample of 274 patients at risk for T2DM, self-efficacy was found to be related to 
weight loss and long-term weight maintenance in the Diabetes Prevention Program (Delahanty, 
Meigs, Hayden, Williamson, & Nathan, 2002). Delahanty et al. (2002) also showed that the 
strength of the correlations between BMI and self-efficacy regarding weight loss differed as a 
function of race/ethnicity; with a stronger association between weight loss and high self-efficacy 
in White nH compared to minorities.  In a sample of 106 overweight to obese Black women, 
high self-efficacy was not associated with weight loss, but greater weight loss was seen in 
patients with lower self-efficacy (Martin, Dutton, & Brantley, 2004). The authors proposed that 
the patients with lower self-efficacy were more accepting of the assistance provided by the 
program, and therefore complied with the weight-loss regimens, whereas the patients with higher 
self-efficacy were either satisfied with their weight or less compliant with the weight loss 
regimens. However, in a community sample of Appalachian patients who were mainly at risk for 
T2DM from being overweight and having low physical activity, self-efficacy was not related to 
being overweight, nor to having low physical activity (Serrano, Leiferman, & Dauber, 2007).  
 
4.2.3.4 Self-efficacy in patients with T2DM and CAD 
In order to keep T2DM and CAD under control, patients must make a number of daily decisions 
regarding medication, glucose monitoring, nutrition, physical activity, and stress management 
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 (Anderson, et al., 2000). Self-efficacy is highly related to T2DM self-management, such as 
glycemic management (HbA1c), dieting (BMI), and physical activity, which are strongly related 
to the control of risk factors (Evenson, et al., 1999; Franz, et al., 2002). 
Although prior research has shown that self-efficacy is associated with better clinical 
outcomes for T2DM and CAD separately, little research has examined the role of self-efficacy in 
patients with both T2DM and CAD and has been conducted longitudinally in diverse 
populations.  A cross-sectional analysis of baseline health status in the BARI 2D study examined 
the association between self-efficacy and HbA1c, systolic blood pressure, and low-density lipids, 
as well as demographic and clinical factors associated with self-efficacy (Sansing, 2007). The 
study population was composed of 1,447 patients with comorbid CAD and T2DM. Better HbA1c 
was positively associated with self-efficacy, even after adjusting for race/ethnicity, age, sex, and 
education. Hispanic ethnicity, history of congestive heart failure, number of hypertension drugs, 
probable neuropathy, and insulin use were negatively associated with self-efficacy (Sansing, 
2007). However, because the analyses were cross-sectional, the direction of association could not 
be established. In addition, because Hispanic ethnicity was highly associated with self-efficacy, 
there is a need to examine further the role of race/ethnicity in the control of risk factors.  
4.3 RATIONALE 
The control of the risk factors associated with T2DM and CAD is not solely a result of the 
prescribed healthcare regimens as given by one’s physician (Jerant, et al., 2005). Psychosocial 
factors play a considerable role in the management of these comorbid diseases, as indicated by 
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 the American Heart Association (AHA, 2009b). Risk factors for CAD and T2DM vary by race, 
with minorities carrying an unequal burden compared to Whites. Winkleby et al. (1994) found 
that Hispanic ethnicity and low self-efficacy were associated with less positive change in 
cardiovascular risk factors. In addition, Hispanic ethnicity has been associated with lower self-
efficacy compared to non-Hispanics (Sansing, 2007). Thus, there is a need to examine self-
efficacy and risk factors in a racially/ethnically diverse population. Self-efficacy is 
conceptualized as a state (transient and situational), as opposed to a trait (inherent and 
permanent), that may change over time, increasing or decreasing based on the successes and 
failures in goal attainment (Gist & Mitchell, 1992). If a person fails to achieve their risk factor 
goals, despite their efforts, they are less likely to adhere properly to medical advice compared to 
someone who succeeds at controlling their risk factors. Therefore, temporal analyses are needed 
to understand how self-efficacy relates to the outcomes of T2DM and CAD management over 
time in a diverse population.   
4.4 SPECIFIC AIMS 
The objective of the proposed study is to examine how baseline self-efficacy is associated with 
the control of risk factors over time in persons with both T2DM and CAD, and to examine 
race/ethnicity as an effect modifier.  Data from the BARI 2D trial, a National Institutes of Health 
(NIH)-sponsored, multi-center, randomized clinical trial of patients with T2DM and 
angiographically-documented stable CAD was used to test the following hypotheses: 
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 1. There will be a positive association between baseline self-efficacy (predictor) and 
follow-up glycemic control (HbA1c) and lifestyle risk factor (BMI and physical 
functioning) outcomes over time. 
2. There will be a time-lag effect between self-efficacy and risk factor control. 
a. Higher self-efficacy (predictor) will be associated with better glycemic and 
lifestyle risk factor control the following year (outcomes).  
b. Better glycemic and lifestyle risk factor control (predictors) will be associated 
with higher self-efficacy the following year (outcome). 
3. Race/ethnicity will serve as an effect modifier for the association between self-
efficacy and glycemic control, BMI, and physical functioning over time in hypotheses 
1 and 2. 
Results of these analyses may provide a better understanding of the relationships and 
disparities among clinical, demographic, and psychosocial factors shaping health outcomes.  This 
research is of importance to the public health field because it examines how differences in the 
confidence of minorities, who are disproportionately affected by T2DM and CAD, may affect 
their clinical prognosis. 
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 4.5 METHODS 
4.5.1 BARI 2D 
BARI 2D is a multicenter clinical trial designed to determine optimal treatment strategies for 
patients with T2DM and documented stable CAD. Using a 2x2 factorial design, BARI 2D 
compared initial elective revascularization with aggressive medical therapy (will be referred to as 
immediate revascularization) versus initial aggressive medical therapy and delayed 
revascularization if symptoms worsen or  are clinically indicated (will be referred to as medical 
therapy), while simultaneously studying an insulin-providing versus an insulin-sensitizing 
strategy of glycemic control to achieve a clinical target of HbA1c <7% (Figure 12) 
(BARI_2D_Study_Group, 2006). 
Randomization to either immediate revascularization or initial medical therapy was 
stratified by BARI 2D site and by intended revascularization to either PCI or CABG as 
determined by a physician.  Follow-up visits occurred monthly for the first six months and 
quarterly thereafter, until the end of the study in 2008. At each follow-up visit, information about 
clinical risk factors, diabetes complications, clinical events, and medications was collected.  Self-
efficacy data were collected annually as part of the quality of life assessments. The mean follow-
up per patient was 5.3 years with a range of 3.5 - 6 years. The BARI 2D primary endpoint was 
all-cause mortality. The composite secondary endpoint was death, non-fatal MI, or stroke.  
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 4.5.2 Population  
Participants were enrolled from 49 clinical sites in the US, Canada, Brazil, Mexico, the Czech 
Republic, and Austria (N=2,368). Eligible participants had a “diagnosis of T2DM and 
angiographically documented CAD for which revascularization was not required for prompt 
control of severe or unstable angina” (BARI_2D_Study_Group, 2006). A physician/investigator 
at each site determined if the patients were eligible for the study based on the inclusion/exclusion 
criteria. Based on the BARI 2D Manual of Operations (BARI_2D_Coordinating_Center, 2002-
2005), inclusion criteria were as follows: diagnosis of T2DM, coronary arteriogram showing one 
or more vessels amenable to revascularization (≥50% stenosis), objective documentation of 
ischemia or subjectively documented typical angina with ≥70% stenosis in at least one artery, 
suitability for coronary revascularization by at least one of the available methods, ability to 
perform all tasks related to glycemic control and risk factor management, age 25 or older, and 
informed written consent (BARI_2D_Study_Group, 2006). Exclusion criteria were as follows: 
definite need for invasive intervention as determined by a cardiologist, any CABG or PCI within 
the past 12 months, class III or IV CHF, creatinine >2.0 mg/dl., HbA1c >13%, need for major 
vascular surgery concomitant with revascularization (e.g., carotid endarterectomy), left main 
stenosis >50%, non-cardiac illness limiting mortality, hepatic disease, fasting triglycerides 
>1,000 mg/dl in the presence of moderate glycemic control (HbA1c ≤8.0%), current alcohol 
abuse, chronic steroid use, known/planned/suspected pregnancy, geographically inaccessible or 
unable to return for follow-up, enrolled in a competing randomized trial or clinical study, and 
unable to understand or cooperate with protocol requirements (BARI_2D_Study_Group, 2006).  
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 For this analysis, patients were limited to US and Canadian sites due to global differences 
in the definition of race/ethnicity and the administration of the self-efficacy assessment (oral 
versus written) (Figure 13). Due to the sample sizes, we examined only White non-Hispanic, 
Black non-Hispanic, and Hispanic patients. Patients in the analyses must have a baseline 
measurement and at least one follow-up measurement for all of the following variables: self-
efficacy, race/ethnicity, HbA1c, DASI, height, and weight (N=1,562).  
4.5.3 Data Collection and Measures 
4.5.3.1 Self-efficacy 
Study participants completed a comprehensive battery of self-reported psychosocial 
measurements including four questions regarding their self-efficacy. The self-efficacy 
assessment was administered at baseline and annually at Years 1 through 6 and was designed to 
measure how confident the patient was in his or her ability to do tasks and activities that relate to 
managing his or her T2DM and CAD in general and specific ways (Appendix A). The self-
efficacy assessment was derived from the Chronic Disease Self-Management Study and was 
found to have high internal consistency (Crohnbach’s α=0.89) (Lorig, 1996). The questions were 
modified from disease management in general to address heart disease and T2DM specifically. 
Each question consisted of a 10-point Likert scale with “1 = not at all confident” and “10 = 
totally confident.” Interest lied in the patients’ confidence in: 1) doing all day-to-day things 
necessary to manage their conditions; 2) doing activities for their T2DM and CAD in order to 
reduce doctor visits; 3) reducing emotional stress associated with their diseases through acts such 
as prayer, meditation, art, and social contact; and 4) doing activities besides medication 
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 adherence, such as exercise, hobbies, and dieting, to reduce the impact of the diseases on their 
daily life.  The final score was an average of the four subscale scores.  
4.5.3.2 Risk factors of interest 
Race was self-reported based on the US Census Classification System as either 1) American 
Indian/Alaskan Native, 2) Asian, 3) Black/African American, 4) Native Hawaiian/Pacific 
Islander, 5) White, or 6) Other (including those of multiple races). Hispanic ethnicity (Latino or 
Spanish origin) was to be indicated regardless of race. HbA1c levels were measured from blood 
samples collected at baseline, and were analyzed at the BARI 2D core Biochemistry Laboratory. 
Physical status was measured by the Duke Activity Status Index (DASI), a 12-item self-reported 
quality of life questionnaire that measures functional capacity or activities of daily living. It 
ranges from 0 (poor) to 58.2 (best) and uses physical work capacity to estimate peak metabolic 
equivalents (Crohnbach’s α=0.67) (Dorian, et al., 2002; Hlatky, et al., 1989). Body mass index 
(kg/m2) was calculated by clinical measurements of weight and height.  
4.5.3.3 Additional variables 
Sex, age, education, cigarette use, history of cancer and cardiovascular complications, probable 
neuropathy, current insulin use at baseline, duration of diabetes, and angina status were self-
reported. Fasting total, low-density lipid cholesterol (LDL), and high-density lipid cholesterol 
were measured from blood samples collected at baseline and were analyzed at the BARI 2D core 
Biochemistry Laboratory. While BARI 2D has data regarding the types of medication prescribed, 
there is no information regarding adherence. With the self-rated health assessment, patients are 
asked to rate their general health as either “Excellent,” “Very Good,” “Good,” “Fair,” or “Poor” 
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 (Lorig, 1996; Ware & Sherbourne, 1992).  Health distress and energy are assessed by a 9-item 
questionnaire in which patients report how they have felt during the past four weeks (Stewart & 
Ware, 1992). Patients are read five answer options that range from “All of the Time” to “None of 
the Time.” 
4.6 STATISTICAL METHODS 
The mean follow-up time for patients was 5.3 years. However, clinical sites joined BARI 2D and 
began recruitment at different time points throughout the study, and the average follow-up time 
for patients varied by site. Therefore, analyses were limited from baseline to follow-up Year 4. 
Missing baseline data were replaced by the mean baseline values for variables with ≤5% missing 
data.  
Normality of the distribution of the self-efficacy scores, HbA1c values, DASI scores, and 
BMI were assessed at baseline. Given the large sample size in this analysis, the distribution of 
baseline self-efficacy score could be considered approximately normal (central limit theorem). 
HbA1c, DASI, and BMI were analyzed using parametric statistics. Differences in baseline 
characteristics of patients were compared by race/ethnicity using chi-square, t-tests, and 
Wilcoxon signed rank tests to identify confounders which are used in the lag models.  
In modeling the relationship between baseline self-efficacy and follow-up risk factor 
status (Aim 1), we used subject-specific mixed models with fixed (i.e., race and sex) and random 
effects (i.e., person-specific intercept and follow-up time variables) to assess within-person 
change over time.  All models included the study treatment assignment and randomization strata, 
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 86 
follow-up time, as well as the baseline values for the risk factor outcome in order to model 
follow-up risk factor status adjusting for baseline level.  Interaction terms between self-efficacy 
and race/ethnicity and between self-efficacy and time were included in the models to test for 
effect modification (Aim 3). The final sets of models were adjusted for demographic and clinical 
confounders.  
In modeling the direction of the association between self-efficacy and follow-up risk 
factor status (Aim 2),  time-lag models were created (Equation 1) (Twisk, 2003). Yit is the 
observation for patient i at year t, βo is the random intercept, β1j is the regression coefficient for 
the predictor variable, Xijt-1 is the predictor variable j for patient i at year t-1, and J is the number 
of predictor variables. In order to examine the cyclic association between self-efficacy and risk 
factors, models were created with 1) self-efficacy (lag) as the predictor and risk factors as the 
outcomes and 2) risk factors (lag) as the predictors and self-efficacy as the outcomes. 
                                    J 
                                  (1)               Yit=βo+Σβ1jXijt-1+… 
                                                                                                                j=1                
 
Within the construct of these models, we adjusted for demographic and clinical confounders and 
tested for interactions between race/ethnicity and self-efficacy and between race/ethnicity and 
the risk factor covariate. Therefore, interaction terms between self-efficacy and race/ethnicity 
were included with the purpose of testing for effect modification (Aim 3). 
 In order to understand which baseline variables were associated with follow-up self-
efficacy scores, subject-specific mixed models were constructed with follow-up self-efficacy 
scores included as dependent variables and years in study and baseline demographics and clinical 
variables as the independent variables, controlling for within subject correlation. The model 
controlled for assigned treatment, randomization strata, age, sex, race/ethnicity, and baseline 
 
 self-efficacy. The variable with the highest p-value was removed from the full model, and the 
model was run again until the most parsimonious model was created.  
 All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, 
2007). The α-levels of significance were 0.05 and 0.01. 
4.7 RESULTS 
4.7.1 Baseline status 
In the US and Canadian sites, 1,562 patients had an assessment at baseline and at one (not 
necessarily at Year 1) or more follow-up time points: 1,533 at Year 1, 1,442 at Year 2, 1,390 at 
Year 3, and 1,184 at Year 4 (Table 10). About a third of the patients were racial/ethnic 
minorities. The main reasons for the decreasing number of patients throughout the duration of 
the study were study close-out and death. Analyses were not conducted with Year 5 (n=948 
including those with no follow-up). The distribution of baseline self-efficacy, HbA1c, DASI, and 
BMI overall and by race/ethnicity are shown in Figures 14-17, and show the same distribution 
for all races/ethnicities. The mean baseline self-efficacy score was 7.76±1.81, median = 8.0, 
skewness = -0.86, kurtosis=0.56, and Kolmogorov-Smirnov p=0.01. The mean baseline HbA1c 
was 7.2%±1.5, the mean baseline DASI score was 16.2%±14.1, and the mean BMI was 
32.7±6.0. Baseline self-efficacy was highly negatively correlated with baseline HbA1c (r=-
0.088, p=0.001) and positively correlated with physical functioning (r=0.37, p<.001), but not 
BMI (r=-0.03, p=0.12) (Table 11). Figure 18 shows mean self-efficacy, HbA1c, DASI, and 
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 BMI over time by race/ethnicity. Self-efficacy and HbA1c both decrease in White nH and Black 
nH patients and increase in Hispanic patients over time. For all patients, DASI increases from 
baseline to Year 1 and decreases from Year 1 – 4, and BMI increases over the years. 
The characteristics of the patients in the analyses are presented in Table 12 overall and 
stratified by race/ethnicity. Overall, the majority of the patients were male (71.4%), and patients 
were approximately 62.8 years of age, completed high school, and were from the United States 
sites (81.5%). Few patients smoked (13.4%) or had cancer (7.2%). Patients’ diabetes control was 
very good, as indicated by an HbA1c of approximately 7.5%. Few patients had self-screened 
probable neuropathy (16.1%) or clinically screened neuropathy (0.8%). Less than a third (30.2%) 
of patients used insulin at baseline. The average duration of T2DM was 10.6 years. Patients were 
on average obese (mean BMI=32.8). The majority of patients had no angina or mild angina 
(Canadian Cardiovascular Classification System [CCS] 1, 2). Regarding the patients’ clinical 
histories, 7.7% had a history of congestive heart failure, 28.7% had a history of MI, and 25.9% 
had a history of peripheral artery disease (Campeau, 1975). The average number of hypertension 
drugs was 2.3±1.0. A large proportion of the patients had a clinical history of hypertension and 
hypercholesterolemia requiring treatment. The mean systolic blood pressure was 130.7±18.6 
mmHg and the median LDL was 92 mg/dl. The mean self-efficacy score was 7.8±1.8. 
Approximately 53.7% of patients rated their health as “Good” to “Excellent.”  The mean 
physical functioning scores was 19.5 (DASI range=0-58.2). Randomization was successful in 
providing a balanced distribution of patients between the cardiovascular and diabetes treatment 
arms; three quarters of the patients were assigned to the PCI revascularization stratum. 
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 The race/ethnicities differed by sex, age, education, United States sites, cigarette use, 
cancer history, HbA1c, neuropathy, insulin use, body mass index, angina status, number of 
hypertension drugs, systolic blood pressure, LDL, and all quality of life measures.  
4.7.2 Baseline self-efficacy and risk factors 
We first examined how baseline self-efficacy was related to follow-up risk factors and if this 
effect was modified by race/ethnicity. The models in Table 13 include the baseline value for the 
risk factor of interest (HbA1c, DASI, or BMI), time (years of follow-up), race/ethnicity (Models 
4-15 only), randomization arms, revascularization strata, baseline self-efficacy, and interaction 
terms between baseline self-efficacy and either time or race/ethnicity (Models 7-15 only). The 
estimated coefficients for self-efficacy and self-efficacy interaction terms are listed for each of 
the follow-up risk factors (outcomes). Baseline self-efficacy was associated with significantly 
lower HbA1c (β=-0.05, p<.001) and higher DASI scores (β=2.23, p<.001), but not with BMI, 
compared to baseline (Models 1-3). Adjusting for race/ethnicity, baseline self-efficacy was 
associated with significantly lower HbA1c (β=-0.04, p=0.009) and higher DASI scores during 
follow-up (β=2.23, p<.001), but not with BMI (Models 4-6). The interaction between baseline 
self-efficacy and time (follow-up years) was not significant; therefore, the effect of self-efficacy 
on HbA1c and BMI did not differ over the follow-up period (Models 7 and 9). However, the 
interaction between baseline self-efficacy and time was significant in the association with DASI 
(p=0.02) indicating that the effect of baseline self-efficacy on physical functioning diminished 
over time (Model 8), and the interaction term was retained in the model. Race/ethnicity was not a 
significant modifier of the association between baseline self-efficacy and HbA1c (2 degrees of 
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 freedom [d.f.] p=0.70), physical functioning (2 d.f. p=0.68), and BMI (2 d.f. p=0.30) (Models 
10-12). After adjusting for baseline confounders, higher baseline self-efficacy remained a 
significant predictor of better HbA1c and higher DASI scores, but not with BMI (Models 13-15). 
Three-way tests of time*race*self-efficacy interactions were non-significant (p's >0.74). 
4.7.3 Baseline factors related to follow-up self-efficacy 
At baseline, Whites nH had the highest self-efficacy scores followed by Black nH and Hispanic 
patients (Table 14). After adjusting for baseline self-efficacy, Blacks had significant 
improvements in self-efficacy scores over the course of the study compared to Whites (β=0.24, 
p=0.004), and Hispanics had less improvements over time than Whites though not significant.  
Older age (β=0.02, p<.001), greater physical function (β=0.02, p<.001), and lower weight (β=-
0.01, p=0.02) were associated with higher self-efficacy during follow-up relative to baseline 
levels. Baseline angina CCS 1 and 2 were also positively associated with improvement in self-
efficacy.  
4.7.4 Time-lag associations between self-efficacy and risk factors 
Next, we examined how self-efficacy was associated with risk factor control in the subsequent 
year, and how risk factor control was associated with self-efficacy in the subsequent year. Table 
15 presents multivariate time-lag models. Models 1-3 include self-efficacy (lag) as a predictor 
and the risk factors as the outcomes. Self-efficacy was associated with a decrease in HbA1c (β=  
-0.020, p=0.01) and an increase in DASI (β=0.373, p<.001) (Models 1 and 2). The interaction 
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 between race/ethnicity and self-efficacy was significant for HbA1c (2 d.f p=0.03); Black nH 
patients showed a significant increase in HbA1c compared to White nH patients. The interaction 
was no longer significant after adjusting for confounders (2 d.f. p=0.06). Models 10-18 present 
the coefficient estimate for risk factors (predictors) and self-efficacy (outcome). HbA1c and BMI 
were both associated with a decrease in self-efficacy (β=-0.082, p<.001 and β=-0.026, p<.001, 
respectively). DASI was associated with an increase in self-efficacy (β=0.021, p<.001). The 
interaction between HbA1c and race/ethnicity was significant (2 d.f. p=0.03, adjusted p=0.02), 
therefore indicating that the association between HbA1c and subsequent self-efficacy is less 
strong in Black nH and Hispanics patients compared with White nH patients.  
4.8 DISCUSSION 
The primary goal of the current study was to examine how self-efficacy relates to risk factors 
(HbA1c, physical functioning, and BMI) and how race/ethnicity modified this association.  The 
main findings from these analyses is that 1) self-efficacy is associated with risk factor control, 
namely glycemic control and physical functioning; and 2) the association between baseline self-
efficacy and risk factors is not dependent on race, but when we look examine the associations 
over time, race/ethnicity is important in the feedback loop.  
First, we demonstrated that higher baseline self-efficacy was associated with better 
follow-up glycemic control and physical functioning in all patients. This is similar to the findings 
from previous research, whose results suggested that self-efficacy could aid in glycemic control 
by increasing adherence to medical regimens (Jerant, et al., 2005; R. Nakahara, et al., 2006; 
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 Robertson & Keller, 1992). Similar to the study by Martin et al. (2004), self-efficacy was 
associated with improved physical functioning in people whose self-efficacy was able to 
increase. In patients with higher baseline self-efficacy scores, physical functioning declined at a 
greater rate compared to patients with lower baseline scores. In the current study, it is possible 
that patients who entered the study with high self-efficacy may have felt their physical 
functioning was good, and therefore did not contribute much effort in trying to increase their 
physical functioning. This may partially account for the greater decline in their DASI scores over 
time as compared to patients with lower self-efficacy.  Baseline self-efficacy was not associated 
with follow-up BMI. Only 9.7% of the BARI 2D patients were normal or underweight at 
baseline, and the average BMI increased throughout the study. Therefore, despite increasing or 
decreasing self-efficacy scores, the patients’ BMIs continued to increase. 
Race/ethnicity did not moderate the effect between baseline self-efficacy and the selected 
risk factors, and these associations remained even after adjusting for factors that varied between 
the races such as age, sex, education, and clinical status. Although Black nH patients reported 
being less confident than White nH patients in their ability to manage their health, Blacks 
patients were still able to improve their HbA1c. In addition, the magnitude of the direction of 
change in physical functioning in Black nH patients was similar to Whites.  These findings may 
indicate a form of health pessimism, in which Blacks are more likely to rate their health as fair or 
poor compared to Whites despite their actual health status (Boardman, 2004; Thomas, et al., 
2010). Here, we have observed that Black nH patients rated their self-efficacy lower than White 
nH despite improvements in glycemic control in Black nH patients. 
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  Second, the current study revealed that self-efficacy was associated with subsequent risk 
factor control for HbA1c, physical functioning, and less strongly for BMI; and these risk factors 
were associated with subsequent self-efficacy.  The evidence points to a cyclic effect (feedback 
loop) as indicated by Bandura’s model of self-efficacy (A. Bandura, 1977). The theory states that 
self-efficacy is associated with outcomes that are associated with future self-efficacy. 
Race/ethnicity moderated the effect between HbA1c and subsequent self-efficacy, with the 
strongest association between self-efficacy and subsequent HbA1c observed in White nH 
patients. As glycemic control improved, self-efficacy increased less in Black nH and Hispanic 
patients compared with Whites. So, in the presence of good glycemic control, Blacks and 
Hispanic patients rated their self-efficacy as low compared to Whites. Again, this is evidence of 
a form of health pessimism in Black patients as it relates to their confidence in being able to 
manage their conditions.  
In previous studies, it was suggested that self-efficacy was associated with medical 
adherence. However, the current study did not measure adherence. We were primarily able to 
measure the clinical and physical outcomes, which is an indicator of the level of adherence to 
medications, diet, and exercise. This study was also limited by the time intervals in which self-
efficacy and the risk factors were measured. One possibility is that self-efficacy may be better 
associated with risk factors at a time span of less than one year. However, for this research, the 
values and measurements were taken annually. Risk factor data for HbA1c and BMI were 
collected more frequently, but annual visits were used in order to provide the same number of 
observations per patient.  
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 In conclusion, in patients with comorbid T2DM and CAD, self-efficacy was related to 
HbA1c and physical functioning, and self-efficacy predicted outcomes, which in turn predicted 
self-efficacy.  This is in line with the feedback loop associated with Bandura’s models of self-
efficacy and outcomes.  In addition, the associations between self-efficacy and glycemic control 
were more apparent in White nH patients compared to Black nH and Hispanic patients. Efforts to 
improve cardiovascular and diabetes outcomes in patients with both T2DM and CAD should 
focus on improving the patients’ confidence in glycemic management, as well as providing 
guidance to increase their daily physical activity to the best of their ability. Positive outcomes 
should be internalized by the patient in order to boost their confidence in continuing proper 
health care management, as well improve their overall quality of life. 
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 4.9 TABLES AND FIGURES FOR PAPER 2 
Table 10. Frequency and percentage of patients by year by race/ethnicity and study status 
at time of study 
Years in Study 
n 
% Baseline 1 2 3 4 
 (n=1,562) (n=1,533) (n=1,442) (n=1,390) (n=1,184) 
Race/Ethnicity      
1067 1052 997 957 817 White nH 
68.31 68.62 69.14 68.85 69 
304 295 275 266 220 Black nH 
19.46 19.24 19.07 19.14 18.58 
191 186 170 167 147 Hispanic 
12.23 12.13 11.79 12.01 12.42 
Study Status      
1056 1041 1003 986 842 Vital status - alive 
67.61 67.91 69.56 70.94 71.11 
34 32 23 15 11 Vital status - unknown 
2.18 2.09 1.6 1.08 0.93 
204 200 190 190 183 Close out – end of study 
13.06 13.05 13.18 13.67 15.46 
104 98 97 96 86 Other 
6.66 6.39 6.73 6.91 7.26 
164 162 129 103 62 Death 
10.5 10.57 8.95 7.41 5.24 
Key: nH – non Hispanic 
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 Table 11. Correlation of baseline self-efficacy and baseline risk factors  
Pearson Correlation Coefficients, N = 1,562 
Probability > |r| under H0: Rho=0 
  Self efficacy score  HbA1c DASI BMI 
Self-efficacy score 1.000 -0.082 0.370 -0.038 
  0.001 <.0001 0.133 
HbA1c -0.082 1.000 -0.050 0.050 
 0.001  0.050 0.051 
DASI 0.370 -0.050 1.000 -0.182 
 <.0001 0.050  <.0001 
BMI -0.038 0.050 -0.182 1.000 
 0.133 0.051 <.0001  
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 Table 12. Baseline table by race/ethnicity  
Characteristic Total White nH Black nH Hispanic 
Overall 
p-value 
 (N=1562) (N=1067) (N=304) (N=191)  
Male, % 71.4 78.1 49.7 69.1 <.001 
Age at study entry, mean, SD 62.8, 8.8 63.4, 8.7 61.6, 9.3 61.2, 8.4 <.001 
Education level, %      
   Some high school or less 24.9 20 29.6 45 <.001 
   High school diploma 26.6 26.6 28.6 23.6  
   Post high school education 29.5 30.3 30.9 23  
   Bachelors degree or higher 19 23.1 10.9 8.4  
United States sites, % 81.5 73.9 97 99 <.001 
Current cigarette smoker, % 13.4 12.1 18.1 13.1 0.03 
Malignancy (cancer), % 7.2 8.4 4.3 5.2 0.02 
HbA1c %, mean, SD 7.5, 1.5 7.3, 1.4 8.0, 1.7 7.7, 1.6 <.001 
HbA1c ≥ 8%, % 30.5 26.6 40.5 36.6 <.001 
Probable neuropathy: screening MNSI ≥7, % 16.1 14.8 13.8 26.7 <.001 
MNSI clinical score, mean, SD 0.8, 0.4 0.8, 0.4 0.9, 0.3 0.9, 0.3 0.05 
Currently taking insulin, % 30.2 26.3 42.1 33 <.001 
Duration of T2DM, mean, SD 10.6, 8.8 10.3, 8.6 11.9, 9.4 10.8, 8.4 0.02 
Body mass index, mean, SD 32.8, 6.0 32.8, 5.8 33.4, 6.9 31.6, 5.3 <.001 
Angina status, %      
   No Angina 43 44.6 36.5 44.5 <.001 
   Angina 1, 2 39.3 40.6 36.8 36.1  
   Angina 3, 4 17.7 14.8 26.6 19.4  
History of congestive heart failure, % 7.7 6.9 9.5 8.9 0.26 
History of myocardial infarction, % 28.7 30.2 26 24.6 0.15 
Peripheral artery disease (PAD), % 25.9 24.6 27.6 30.4 0.19 
Number of hypertension drugs, mean, SD 2.3, 1.0 2.2, 1.0 2.6, 1.0 2.1, 0.9 <.001 
Hypercholesterolemia requiring treatment, % 83.9 83.35 85.95 84.04 0.56 
Systolic blood pressure  average, mean, SD 130.7, 18.6 128.9, 17.5 136.7, 20.0 131.4, 19.9 <.001 
Systolic blood pressure > 140, % 24.8 21.5 36.5 25.1 <.001 
LDL mg/dl, median (Q1-Q3) 92 (73-111) 89 (71-107) 101 (82-127) 94 (71-110) <.001 
LDL ≥100 mg/dl, % 35.1 30.5 49.7 37.7 <.001 
Self efficacy score (0-10), mean, SD 7.8, 1.8 7.9, 1.7 7.7, 1.9 7.0, 2.0 <.001 
Self rated health category, %     <.001 
   Excellent 1.34 1.59 0.99 0.52  
   Very good 10.95 12.09 7.57 9.95  
   Good 41.42 46.49 32.57 27.23  
   Fair 33.8 29.62 44.41 40.31  
   Poor 12.48 10.22 14.47 21.99  
DASI (0-58.2), mean, SD 19.5, 14.1 20.9, 14.2 17.9, 13.2 14.1, 13.3 <.001 
Energy score (0-100), mean, SD 47.0, 21.6 47.2, 21.8 49.1, 20.0 42.6, 22.2 0.00 
Health distress score (0-100), mean, SD 43.0, 25.4 41.6, 24.8 43.0, 25.9 51.0, 26.4 <.001 
Glycemic arm treatment, % 50.4 50.9 47.4 52.9 0.43 
Cardiovascular treatment, % 48.7 48.1 48.7 52.4 0.55 
Revascularization strata, %     <.001 
CABG 24.0 26.1 14.8 26.7  
PCI 76.0 73.9 85.2 73.3  
97 
 
 98 
 
Key: DASI – Duke Activity Status Index, MI – myocardial infarction, LDL – low density lipids, MNSI – Michigan 
Neuropathy Screening Instrument, Q1-Q3 – first and third quartile 
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Table 13. Multivariate mixed models of baseline self-efficacy (predictor) and risk factors 
(outcome)  
   Separate outcomes  
  HbA1c DASI BMI 
Models * Predictors and Interaction Terms Est. P-value Est. P-value Est. P-value 
1-3 
Baseline self-efficacy  
(race/ethnicity not in model) -0.05 <.001 2.23  <.001 -0.14 0.11 
           
4-6  Baseline self-efficacy -0.03 0.009 2.23 <.001 -0.13 0.15 
           
7-9  Baseline self-efficacy -0.06 0.008 0.84 <.001 -0.007 0.84 
 Baseline self-efficacy*Time (interaction) -0.001 0.90 -0.14 0.02 0.01 0.40 
           
10-12  Baseline self-efficacy -0.03 0.07 0.62 <.001 0.04 0.28 
 
Baseline self-efficacy*Race/ethnicity  
(2 d.f. test)  0.70  0.68   0.30 
   Baseline self-efficacy*Black nH (interaction) -0.006 0.86 -0.30 0.38 -0.11 0.13 
   Baseline-self-efficacy*Hispanic (interaction) -0.03 0.40 -0.08 0.84 -0.06 0.46 
        
       13-15** Baseline self-efficacy  -0.03 <.001 0.87 <.001 0.03 0.32 
 Time  0.02 0.04 0.15 0.76 0.14 <.001 
 Baseline self-efficacy*Time (interaction)   -0.14 0.02   
       
Note: Tests of time*race*self-efficacy interactions were non-significant (p's >0.74). 
* All models include race/ethnicity (with the exception of models 1-3), the baseline value for the risk factor of 
interest, time in follow-up years, randomized diabetes (insulin sensitizers versus insulin providers) and 
cardiovascular (medical therapy versus immediate revascularization) treatment assignment, and revascularization 
strata (coronary artery bypass graft versus percutaneous coronary intervention). 
** Models 13-15 additionally adjust for baseline values of race/ethnicity, HbA1c, BMI, DASI, age, post high school 
education, USA sites, malignancy (cancer), clinical neuropathy, insulin use, duration of diabetes, angina status, 
number of hypertension drugs, systolic blood pressure, and low density lipids. 
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Table 14. Multivariate model of baseline variables associated with follow-up self-efficacy 
Effect Estimate p-value 
Black nH vs. White nH 0.24 0.004 
Hispanic vs. White nH -0.17 0.11 
Age (per year) 0.02 <.001 
Body mass index -0.01 0.02 
Duke Activity Status Index 0.02 <.001 
Clinical neuropathy -0.06 0.004 
Angina 3, 4, Unstable vs. none 0.14 0.13 
Angina 1, 2 vs. none 0.28 0.003 
Insulin Providing vs. Insulin Sensitizing -0.07 0.31 
Revascularization vs. Medical Therapy 0.05 0.49 
CABG vs. PCI 0.12 0.13 
Baseline self-efficacy 0.31 <.001 
Key: CABG – coronary artery bypass graft, PCI – percutaneous coronary intervention 
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Table 15. Time-lag models of self-efficacy and risk factors  
Predictor: Self-efficacy (Lag), Outcome: Risk Factor HbA1c DASI BMI 
Models Predictor Est. P-value Est. P-value Est. P-value 
1-3 Self-efficacy -0.020 0.01 0.373 <.001 -0.025 0.09 
             
4-6 Self-efficacy -0.029 0.002 0.346 <.001 -0.032 0.08 
 Self-efficacy*Race/ethnicity (2 d.f. test)  0.03   0.38  0.87 
   Self-efficacy*Black nH 0.050 0.01 -0.075 0.72 0.019 0.64 
   Self-efficacy*Hispanic -0.005 0.82 0.299 0.21 -0.0001 0.99 
           
7-9** Self-efficacy -0.024 0.01 0.302 <.001 -0.022 0.22 
 Self-efficacy*Race/ethnicity (2 d.f. test)   0.06   0.41   0.73 
   Self-efficacy*Black nH 0.044 0.03 -0.070 0.73 0.024 0.53 
   Self-efficacy*Hispanic -0.005 0.84 0.285 0.23 0.016 0.72 
       
Predictor: Risk Factor (Lag), Outcome: Self-efficacy HbA1c DASI BMI 
Models Predictor 
Self-efficacy 
Est. P-value 
Self-efficacy 
Est. P-value 
Self-efficacy 
Est. P-value 
10-12 Risk factor -0.082 <.001 0.021 <.001 -0.026 <.001 
             
13-15 Risk factor -0.123 <.001 0.018 <.001 -0.029 <.001 
 Risk factor*Race/ethnicity (2 d.f. test)  0.03   0.05  0.66 
   Risk factor*Black nH 0.090 0.04 0.012 0.02 0.008 0.50 
   Risk factor*Hispanic 0.113 0.03 0.006 0.34 0.013 0.47 
           
16-18** Risk factor -0.101 <.001 0.016 <.001 -0.013 0.06 
 Risk factor*Race/ethnicity (2 d.f. test)  0.02   0.09  0.97 
   Risk factor*Black nH 0.083 0.05 0.011 0.03 0.001 0.93 
   Risk factor*Hispanic 0.125 0.02 0.004 0.53 0.003 0.85 
Three way tests of lag variable*race/ethnicity*time were non-significant (2 d.f. p’s>0.15). 
Key: BMI – body mass index, DASI – Duke Activity Status, d.f. – degrees of freedom, Est. - coefficient estimate,  nH – non Hispanic, 
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* All models include race/ethnicity, the baseline value for the risk factor of interest, time in follow-up years, randomized diabetes (insulin sensitizers versus 
insulin providers) and cardiovascular (medical therapy versus immediate revascularization) treatment assignment, and revascularization strata (coronary artery 
bypass graft versus percutaneous coronary intervention). 
** Models 7-9 and 16-18 additionally adjust for baseline values of HbA1c, BMI, DASI, age, post high school education, USA sites, malignancy (cancer), clinical 
neuropathy, insulin use, duration of diabetes, angina status, number of hypertension drugs, systolic blood pressure, and low density lipids. 
 Figure 12. BARI 2D enrollment and randomization. 
Modified from BARI_2D_Study_Group. (2009). A randomized trial of therapies for type 2 
diabetes and coronary artery disease. N Engl J Med, 360(24), 2503-2515. 
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Key: BSE – Baseline self-efficacy, F/U – follow-up 
Figure 13. Population flowchart for Aim 2 
104 
 
 0 1 2 3 4 5 6 7 8 9 10
0
5
10
15
20
25
Pe
rc
en
t
Minimum 1.00
Median 8.00
Maximum 10.00
Std Deviation 1.81
Baseline Self-efficacy Score
Curve: Normal(Mu=7.7599 Sigma=1.8111)
0
5
10
15
20
25
Pe
rc
en
t
Minimum 1.00
Mean 7.93
Median 8.00
Maximum 10.00
Std Deviation 1.71W
hi
te
 n
H
0
5
10
15
20
25
Pe
rc
en
t
Minimum 1.00
Mean 7.65
Median 8.00
Maximum 10.00
Std Deviation 1.91B
la
ck
 n
H
0 1 2 3 4 5 6 7 8 9 10
0
5
10
15
20
25
Pe
rc
en
t
Minimum 1.00
Mean 7.00
Median 7.00
Maximum 10.00
Std Deviation 2.00H
is
pa
ni
c
Baseline Self-efficacy Score
 
Figure 14. Distribution of baseline self-efficacy scores overall and by race/ethnicity 
105 
 
 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0
0
5
10
15
20
25
30
35
Pe
rc
en
t
Minimum 5.00
Median 7.20
Maximum 13.60
Std Deviation 1.53
Baseline HbA1c
Curve: Normal(Mu=7.5236 Sigma=1.5282)
0
5
10
15
20
25
30
35
Pe
rc
en
t
Minimum 5.00
Mean 7.33
Median 7.00
Maximum 12.60
Std Deviation 1.40W
hi
te
 n
H
0
5
10
15
20
25
30
35
Pe
rc
en
t
Minimum 5.00
Mean 8.06
Median 7.70
Maximum 13.60
Std Deviation 1.74B
la
ck
 n
H
4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0
0
5
10
15
20
25
30
35
Pe
rc
en
t
Minimum 5.30
Mean 7.76
Median 7.40
Maximum 12.20
Std Deviation 1.64H
is
pa
ni
c
Baseline HbA1c
 
Figure 15. Distribution of baseline HbA1c overall and by race/ethnicity 
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Figure 16. Distribution of baseline DASI scores overall and by race/ethnicity 
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Figure 17. Distribution of baseline BMI overall and by race/ethnicity 
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Figure 18. Line graphs of mean self-efficacy scores, HbA1c, DASI scores, and BMI by race/ethnicity over time  
 5.0  PAPER 3: SELF-EFFICACY AND CARDIOVASCULAR ENDPOINTS 
5.1 ABSTRACT 
OBJECTIVE: The purpose of this study was to examine the association between self-efficacy 
and the cardiovascular outcomes death, death/myocardial infarction (MI)/stroke, subsequent 
revascularization procedures, and angina. 
METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes 
(BARI 2D) trial, we examined 1,817 patients from the United States (US) and Canada sites. 
Patients were randomized to receive treatment for Type 2 diabetes mellitus (T2DM) by either 
insulin sensitizing drugs or insulin providing drugs, and for coronary artery disease (CAD) by 
either immediate revascularization or medical therapy.  The self-efficacy assessment from the 
Chronic Disease Self-Management Study was administered at baseline and annually throughout 
the study. Kaplan-Meier rates were used to examine all of the outcomes, except for angina. 
Mixed models were used to examine the presence of angina over time. We tested for interactions 
between self-efficacy and cardiac treatment. 
RESULTS: Compared to fair-excellent self-efficacy, poor baseline self-efficacy was associated 
with an increased risk of a composite endpoint of death/MI/stroke (hazard ratio [HR]=1.34, 
p=0.01), subsequent revascularizations (HR=1.30, p=0.004), subsequent PCIs (HR=1.43, 
p<.001), and angina (odds ratio [OR]=1.11, p<.001). These associations were not significant 
after adjusting for baseline demographic and clinical covariates. A decrease in self-efficacy from 
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 baseline to Year 1 was a powerful predictor of death (adjusted HR=2.32, p<.001) and 
death/MI/stroke (HR=1.79, p<.001).    
CONCLUSIONS: Although poor baseline self-efficacy was associated with an increased risk of 
death/MI/stroke, subsequent revascularization procedures and angina, these associations were 
primarily explained by differences in baseline risk factors. The negative change in self-efficacy 
was a more powerful predictor of BARI 2D’s primary and secondary endpoints. 
5.2 INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular events in 
patients with coronary artery disease (CAD) (Stamler, Vaccaro, Neaton, & Wentworth, 1993). 
There are multiple methods to treat these conditions, namely medical therapy and cardiac 
revascularization. However, the psychological predictors of cardiac morbidity and mortality are 
gaining more attention from researchers as, “The first step toward targeted prevention measures” 
(Sarkar 2009, page 1). Poor self-efficacy is associated with poor health status and cardiac 
severity, increased physiological stress, and poor patient behaviors such as insufficient adherence 
to prescribed medications (Sarkar, 2007; Murray et al., 2007; Tu et al., 2005). Yet, the extent to 
which cardiac morbidity/mortality is associated with self-efficacy is unclear.  
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was 
a randomized clinical trial that compared therapies for patients with T2DM and CAD. There was 
no significant difference between five-year survival rates of patients randomized to immediate 
revascularization or medical management (88.3% vs. 87.8%, respectively; p=0.97); nor, did 
freedom from the composite of death/myocardial infarction (MI)/stroke differ between the two 
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 groups (77.2% vs. 75.9%, respectively; p=0.70). However, in patients who were selected for 
coronary artery bypass graft (CABG), as opposed to percutaneous coronary intervention (PCI) 
procedures, the cardiovascular event rate was significantly lower in the revascularization group 
as compared to the medical therapy group (22.4% vs. 30.5%, respectively; p=0.01) 
(BARI_2D_Study_Group, 2009). Quality of life indices, such as self-efficacy, were collected in 
order to examine additional risk factors for cardiac events. It is unknown how self-efficacy may 
affect the survival and freedom from cardiac events in this patient population, and whether this 
varies by treatment regimen. 
Using data from the BARI 2D trial, the primary aim of this paper is to examine how self-
efficacy is associated with the adverse cardiac events of death, myocardial infarction, stroke, 
subsequent revascularization, and angina. The secondary aim is to examine how these 
associations differ by the types of randomized cardiovascular therapy: either medical therapy or 
revascularization. The definitions and epidemiology of the adverse clinical events associated 
with CAD (death, MI, stroke, angina, and subsequent revascularizations), cardiovascular 
therapies, and self-efficacy, will be presented first. Then we will examine clinical event rates by 
self-efficacy level, and determine whether revascularization treatment interacts with this 
psychological risk factor. This analysis is novel in two respects: 1) this study involves a cardiac 
patient population with Type 2 diabetes mellitus (T2DM) – a risk factor for adverse 
cardiovascular morbidity and mortality; and 2) it is the first study to examine how self-efficacy is 
associated with mortality with respect to the type of cardiovascular therapy.  
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 5.2.1 Cardiac events 
5.2.1.1 Coronary artery disease 
Coronary artery disease (CAD) is characterized by atherosclerotic plaque build-up in the arteries, 
resulting in inadequate circulation of blood to the heart, brain, and surrounding tissues. 
Approximately 81.1 million adults in America (36.9%) have some form of CAD, which was the 
leading cause of death in 2006, accounting for 831,100 deaths (NHLBI, 2009). Black non-
Hispanics (nH) have higher rates of CAD compared to Whites and Hispanics (AHA, 2010).  
CAD was also the leading cause of death in 2005 accounting for 36.2% of deaths in White nHs, 
33.6% in Black nHs, and 39.6% in Hispanics (CDC, 2008).  
A major clinical risk factor for CAD is T2DM. If untreated or poorly managed, T2DM 
can result in blindness, amputations, end stage renal disease (ESRD), and cardiovascular 
complications such as MI (heart attack) and stroke (NIDDK, 2007). In 2004, CAD disease 
accounted for 68% of the deaths in people with T2DM aged 65 years or older (NIDDK, 2007). 
Based on 20 years of surveillance data, the Framingham Heart Study found that patients with 
diabetes had a two- to three-fold increased risk of CAD compared to patients without diabetes 
(Kannel & McGee, 1979). 
5.2.1.2  Myocardial infarction 
MI is a rapid necrosis of the myocardium due to interrupted blood flow from the arteries. In 
2006, 8.5 million (3.6%) people in the US experienced a MI; and MI accounted for 141,500 
deaths (AHA, 2010). The prevalence rates in White nH males and females were 5.1% and 2.6%, 
respectively. In Black nH males and females, the rates were 3.6% and 2.9%, respectively, and in 
Mexican American males and females, they were 2.6% and 2.0%, respectively (AHA, 2010). 
113 
 
 5.2.1.3 Stroke 
A stroke (cerebrovascular accident) is developing brain damage caused by interrupted blood flow 
to the brain due to a hemorrhage (bleeding in the brain) or ischemia (restricted blood flow). In 
2006, the US prevalence of strokes was 6.4 million (2.9%) and the incidence of new and 
recurrent strokes was 795,000. Strokes accounted for 137,000 deaths in the US (AHA, 2010). 
The prevalence of stroke differs by gender and race/ethnicity, with higher rates reported in 
females and racial/ethnic minorities. In 2006, the prevalence rate in White nH males and females 
was 2.3 and 3.1%, respectively, and in Black nHs, 3.8% and 4.3%, respectively. In Hispanics and 
Mexican Americans, the rates ranged from 2.6 – 3.1%. 
5.2.1.4 Angina  
Angina is a treatable cardiovascular complication marked by intermittent chest pain due to 
reduced oxygen to the heart (Campeau, 1975). Classic angina, as defined by the Canadian 
Cardiovascular Society (CCS) Functional Classification of Angina, is based on the activity that 
evokes pain and physical limitations (Campeau, 1975). The classification system ranges from 
Class 1 to Class 4, with Class 1 being evoked by strenuous activities and Class 4 evoked by less 
strenuous activities: 
• Class I: Prolonged exertion with no physical limitations 
• Class II: Walking more than two blocks or more than one flight of stairs with slight 
physical limitations 
• Class III: Walking more than two blocks or more than one flight of stairs with marked 
physical limitations 
• Class IV: Minimal activity or at rest with severe physical limitations 
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 5.2.2 CAD Treatment 
Treatment options for CAD include a) medical management with diet, exercise, and medicine; or 
b) revascularization either by CABG or PCI. CABG is an invasive procedure in which a healthy 
blood vessel is grafted onto the heart to bypass the blocked part of the coronary artery. Due to 
the invasive nature of the procedure, it is not common to be revascularized by CABG more than 
once.  PCI is a less invasive procedure in which a balloon–tipped catheter is placed into the 
diseased arteries of the heart (AHA, 2009). In the event of a subacute (coagulated) stent or 
worsening CAD, subsequent revascularizations by PCI can be performed. 
5.2.3 Self-efficacy  
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The patient’s self-confidence plays a crucial role in the ability to manage potentially harmful and 
fatal chronic conditions (Lorig, 1996). Self-efficacy, the belief that one is able to make changes 
necessary for self-management, has been found to be associated with glycemic control and 
cardiac symptom burden (A. Bandura, 1977; Chlebowy & Garvin, 2006b; Sarkar, et al., 2007; 
Sullivan, et al., 1996). The idea of self-efficacy originates from Albert Bandura’s social learning 
theory, which proposes that behaviors are learned from observing and analyzing the behaviors of 
others (A. Bandura, 1977). 
Joekes et al. (2007) hypothesized that patients with low self-efficacy are prone to poorer 
clinical outcomes as a result of MI, because their low self-efficacy impairs their ability to seek 
clinical help in an optimal time window. Only 20% of people who have an acute MI reach 
medical care within an optimal time window; 75% of this delay is attributed to the patient’s 
decision to seek help. Joekes found that during an MI, low self-efficacy combined with negative 
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outcome expectancies were associated with an increased delay in reaching the hospital promptly 
(Joekes, Van Elderen, & Schreurs, 2007).  
Self-efficacy has also been studied extensively in CAD patients after a non-fatal MI. 
Findings show that self-efficacy was one of the most relevant psychological constructs in cardiac 
rehabilitation. Moore et al. (2007) revealed that in a sample of 248 participants treated for CAD 
or an MI, self-efficacy was the most salient psychological mediator in the prediction of health 
status. Self-efficacy predicted MI patients' self-management behaviors during the three months 
following the events (Joekes, et al., 2007).  
In Paper 2, an inverse cross-sectional relationship was demonstrated between baseline self-
efficacy and angina in patients with both T2DM and CAD. Patients who began the study with 
self-efficacy scores >8 (on a 1 [poor] -10 [best] point scale) were more likely to be absent of 
classic angina compared to patients with self-efficacy scores ≤8 (46.2% vs. 39.8%, p=0.02). 
Sarkar et al. (2007) have shown a negative association between cardiac symptom burden and 
self-efficacy; however, no direct association between self-efficacy and angina was demonstrated. 
Measuring the patients’ self-efficacy about their cardiac management provides a quick 
and powerful assessment of cardiac symptom burden, function, and outcomes in patients with 
CAD (Sarkar et al., 2007 & 2009). In an observational cohort study of ambulatory patients with 
stable coronary heart disease, Sarkar et al. (2007) showed that even after controlling for cardiac 
risk factors and symptoms, self-efficacy was a strong predictor of cardiac health status. For each 
standard deviation decrease in the self-efficacy score, the odds for cardiac symptom burden more 
than doubled (adjusted odds ratio [OR] = 2.1, p = .001). In the same cohort of patients, Sarkar et 
al. (2009) evaluated the association between self-efficacy and objective measures of cardiac 
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function, heart failure hospitalization, and all-cause mortality (Sarkar, et al., 2009). Self-efficacy 
was measured using the 5-item Sullivan Self-Efficacy to Maintain Function Scale. Among 1,024 
patients with CAD, self-efficacy was an effective proxy for clinical risk factors in predicting 
heart failure hospitalizations (OR per standard deviation [sd] decrease = 1.4, p = 0.0006) and all-
cause mortality (OR per SD decrease = 1.4, p < 0.0001) (Sarkar, et al., 2009). The interaction 
between self-efficacy and depressive symptoms was not significant. After adjusting for 
demographics, medical history, medication use, depressive symptoms, and social support, the 
association of cardiac self-efficacy with both heart failure hospitalization and mortality was 
explained by worse baseline cardiac function. However, one of the main limitations of this study 
was the use of a predominately older, lower-income male population which 1) limits the 
generalizability of the results; and 2) is a population at risk for T2DM – a clinical risk factor not 
documented in this study.  
In a sub-study of BARI 2D by Sansing et al. (Paper 2), self-efficacy was examined in 
patients with both CAD and T2DM. Patients with lower baseline self-efficacy scores carried a 
greater burden of cardiac risk factors compared to patients with baseline self-efficacy scores >8. 
Compared to patients with baseline self-efficacy scores >8, those patients with poorer baseline 
self-efficacy scores (≤8) were more likely to be female, Hispanic, and have a lower education. 
These patients also had significantly worse clinical profiles, including higher HbA1c, greater 
neuropathy, more severe angina, a history of congestive heart failure, and higher number of 
hypertension drugs. There were no differences in age, distribution of US sites, malignancy 
(cancer), history of MI, systolic blood pressure, and low density lipids between those with scores 
<8 and ≥8. In a longitudinal analysis of the BARI 2D study, results showed a feedback loop 
between increased self-efficacy and better risk factor control. It was also noted that patients 
 
 randomized to an initial strategy of revascularization, by PCI or CABG, and a strategy of 
medical therapy had similar self-efficacy over the subsequent four years of follow-up. 
5.2.4 Psychological factors and cardiac therapies 
For patients with coronary disease, revascularization has been shown to be associated with better 
quality of life compared to no revascularization. In a report by Eagle et al. (2004) in the 
American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for 
Coronary Artery Bypass Graft Surgery, both CABG and PCI were related to greater health-
related quality of life (HRQoL) compared to traditional medical therapy (Committee, et al., 
2002). PCI provided improvements in HRQoL in the earlier post-procedure compared to CABG, 
while CABG improved health-related quality of life better than traditional medical therapy for up 
to five years post-surgery (Hofer, Doering, Rumpold, Oldridge, & Benzer, 2006).  
5.3 RATIONALE 
The primary aim of this analysis was to examine the relationship between self-efficacy and the 
cardiovascular clinical endpoints of the BARI 2D study, all-cause mortality, a composite of 
death, MI, and stroke, subsequent revascularization (any revascularization, PCI and CABG), and 
angina. The secondary aim was to examine how these relationships vary by cardiac treatment 
(initial revascularization or medical therapy). This goal is important because it examines how the 
confidence of a person with chronic conditions can affect serious adverse events and mortality. 
These conditions are sometimes physically painful, limit the patients’ mobility, significantly 
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 decrease their lifespan, can include large medical costs, and involve lifestyle changes for them, 
as well as for their caregivers and families. 
Self-efficacy is needed to adapt to these lifestyle changes, and poor self-efficacy has been 
associated with poorer cardiac status, which results in increased cardiac events and 
complications (Sarkar, et al., 2009). This literature has shown that patients with poor self-
efficacy have greater cardiac symptom burden compared to patients with high self-efficacy. 
Given that many risk factors are associated with poorer self-efficacy, one can hypothesize that 
poor self-efficacy is associated with worse clinical outcomes. The majority of the literature 
regarding self-efficacy and cardiovascular symptoms and outcomes was based on observational 
data from the Heart and Soul Study resulting in potential confounders between the types of 
treatments used and the clinical and demographic profile of the recipients (Sarkar, et al., 2007; 
Sarkar, et al., 2009; Sarkar, et al., 2006).  For instance, patients who were revascularized may 
have had worse cardiac clinical status compared to patients who were not revascularized at all. 
In the BARI 2D clinical trial, the randomized cardiac therapy (prompt revascularization 
vs. medical therapy) was not associated with patient self-efficacy during follow-up.  Moreover, 
the cardiac treatment was not associated with the primary and principal secondary BARI 2D 
endpoints of death and the composite of death, MI and stroke, respectively 
(BARI_2D_Study_Group, 2009). However, the rate of subsequent revascularization and the 
prevalence of angina were significantly higher among patients randomized to initial medical 
therapy compared to patients randomized to revascularization. Using prospective data from a 
randomized clinical trial, we will examine the relationship between self-efficacy and 
cardiovascular outcomes overall, and with respect to the cardiac treatment.  
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 5.4 SPECIFIC AIMS 
In order to further examine if self-efficacy is related to clinical outcomes of death, 
death/myocardial infarction/stroke, subsequent revascularization, and angina in patients with 
comorbid T2DM and CAD, the hypotheses are as follows: 
H1: Lower self-efficacy at baseline will be associated with an increased risk of each of 
the clinical endpoints. 
H2: Lower self-efficacy at baseline will be associated with an increased risk of each of 
the clinical endpoints among patients randomized to medical therapy and 
revascularization. 
5.5 METHODS 
5.5.1 BARI 2D Study design 
BARI 2D is a multicenter clinical trial designed to determine optimal treatment strategies for 
patients with T2DM and documented stable CAD. Using a 2x2 factorial design, BARI 2D 
compared initial revascularization with intensive medical therapy (will be referred to as prompt 
revascularization) versus initial intensive medical therapy and delayed revascularization if 
symptoms worsen or are clinically indicated (will be referred to as medical therapy), while 
simultaneously studying an insulin-providing versus an insulin-sensitizing strategy of glycemic 
control to achieve a clinical target of HbA1c <7%  (BARI_2D_Study_Group, 2006). 
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 Randomization was stratified by BARI 2D site and by the intended revascularization, PCI 
or CABG, as determined by a physician.  Follow-up visits occurred monthly for the first six 
months and quarterly thereafter, until the end of the study in 2008. At each follow-up visit, 
information about clinical risk factors, diabetes complications, clinical events, and medications 
was collected.  Self-efficacy data were collected annually as part of the quality of life 
assessments. The mean follow-up per patient was 5.3 years with a range of 3.5 to 6 years. The 
BARI 2D primary endpoint was all-cause mortality. The composite secondary endpoint was 
death, non-fatal MI, or stroke.  
5.5.2 Population 
Participants were enrolled from 49 clinical sites in the US, Canada, Brazil, Mexico, the Czech 
Republic, and Austria (N=2,368). Eligible participants had T2DM and had angiographically 
documented CAD that did not require immediate revascularization for control of symptoms 
(BARI_2D_Study_Group, 2006). Inclusion criteria were as follows: diagnosis of T2DM, 
coronary arteriogram showing one or more vessels amenable to revascularization (≥50% 
stenosis), documentation of ischemia or documented classic angina with ≥70% stenosis in at 
least one artery, suitability for coronary revascularization by at least one of the available 
methods, ability to perform all tasks related to glycemic control and risk factor management, age 
25 or older, and informed written consent (BARI_2D_Study_Group, 2006). Patients were 
excluded if there was a definite need for invasive intervention as determined by a cardiologist, 
any CABG or PCI within the past 12 months, class III or IV CHF, creatinine >2.0 mg/dl, HbA1c 
>13%, need for major vascular surgery concomitant with revascularization (e.g., carotid 
endarterectomy), left main stenosis >50%, non-cardiac illness limiting mortality, hepatic disease, 
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 fasting triglycerides >1,000 mg/dl in the presence of moderate glycemic control (HbA1c ≤8.0%), 
current alcohol abuse, chronic steroid use, known/planned/suspected pregnancy, geographically 
inaccessible or inability to return for follow-up, enrolled in a competing randomized trial or 
clinical study, and inability to understand or cooperate with protocol requirements 
(BARI_2D_Study_Group, 2006).  
5.5.3 Data Collection and Measures 
5.5.3.1 Self-efficacy 
The self-efficacy assessment was administered at baseline and annually at Years 1 through 6.  
The instrument was designed to measure how confident the patient was in his or her ability to do 
tasks and activities that relate to managing his or her T2DM and CAD in general and specific 
ways (Appendix A). The term “management” may be interpreted as something as simple as 
trying to monitor glucose regularly or to adhering to a more complex regimen of a specific diet 
with regular exercise. Patients were encouraged to personally consider what tasks and activities 
he or she completed on a day-to-day basis, in order to measure confidence in the ability to keep 
T2DM and CAD “under control.” The self-efficacy assessment was derived from the Chronic 
Disease Self-Management Study (Lorig, 1996). The questions were modified from general 
disease management to heart disease and T2DM specifically. Each question consisted of a 10-
point Likert scale with “1 = not at all confident” and “10 = totally confident.” Interest lied in the 
patients’ confidence in: 1) doing all day-to-day things necessary to manage their conditions; 2) 
doing activities for their T2DM and CAD in order to reduce doctor visits; 3) reducing emotional 
stress associated with their diseases through acts such as prayer, meditation, art, and social 
contact; and 4) doing activities besides medication adherence, such as exercise, hobbies, and 
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 dieting to reduce the impact of the diseases on their daily life.  The individual items in the self-
efficacy score had high internal consistency (Cronbach’s α = 0.92). 
5.5.3.2 Endpoints 
The primary endpoint for the BARI 2D trial was all-cause mortality and the secondary composite 
endpoint was death, nonfatal myocardial infarction, or stroke. Definitions for endpoints and 
ascertainment methods were provided in the main trial report (BARI 2D Study Group, 2006). 
Cause of death and stroke were classified and adjudicated by the BARI 2D Mortality and 
Morbidity Committee. The committee was blinded to randomization assignment, treatment 
received, and additional clinical data. MI was classified by a blinded independent Core 
Electrocardiography Laboratory. The definition of a subsequent revascularization was based on 
the randomization arm. For patients randomized to medical therapy, a subsequent 
revascularization was the first revascularization in BARI 2D. For patients randomized to the 
prompt revascularization arm, the subsequent revascularization was the first one following their 
initial protocol-driven revascularization. Angina was assessed at the BARI 2D annual clinic 
visits and was categorized using the Canadian Cardiovascular Society (CCS) classification 
system (Campeau, 1976).  
5.5.3.3 Demographic and Clinical variables 
Race was self-reported based on the US Census Classification System as: 1) American 
Indian/Alaskan Native; 2) Asian; 3) Black/African American; 4) Native Hawaiian/Pacific 
Islander; 5) White; or 6) Other (including those of multiple races). Hispanic ethnicity (Latino or 
Spanish origin) was indicated regardless of race. A detailed clinical history was recorded at study 
entry including smoking status, history of cancer and cardiovascular complications, duration of 
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 diabetes, neuropathy symptoms, and diabetes medication use. Body mass index (BMI) (kg/m2) 
was calculated by clinical measurements of weight and height. HbA1c levels, fasting total, low-
density lipid cholesterol (LDL), and high-density lipid cholesterol (HDL) were measured from 
blood samples collected at baseline and were analyzed at the BARI 2D Core Biochemistry 
Laboratory. BARI 2D collected data regarding medications prescribed, but there is no 
information regarding patient adherence in this study.  
5.5.3.4 Statistical Methods 
Analyses were restricted to patients with a self-efficacy score at baseline. Moreover, due to 
language barriers and method of administration, only patients from US and Canadian sites were 
included in this analysis. Normality of the distribution of the self-efficacy scores was assessed to 
be approximately normal. Baseline self-efficacy was categorized into quartiles, and then, based 
on the left skewed distribution, was dichotomized as Poor (score 1-6.7) vs. Fair/Good/Excellent 
(6.75-10). Change is calculated as the Year 1 self-efficacy score minus the baseline self-efficacy 
score. Change from baseline to Year 1 was examined categorically as: ≥1.5 decrease, moderate 
change between -1.5 and 1.5 (reference group), and ≥1.5 increase. The value of 1.5 was chosen 
based on the standard deviation of the change between baseline and Year 1 (Paper 1).  
Baseline demographics and clinical characteristics were compared to baseline self-
efficacy categories. Differences in baseline characteristics were compared using chi-square, t-
tests, and Wilcoxon signed-rank tests. Five year Kaplan-Meier (KM) rates of all cause mortality, 
death/MI/stroke, subsequent procedure, subsequent PCI, and subsequent CABG were calculated 
according to the baseline self-efficacy scores (Poor vs. Fair-Excellent), and compared using log-
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 rank statistics. The KM event rates were examined overall and within each cardiac 
randomization arm (prompt revascularization and medical therapy). 
Hazard ratios for baseline self-efficacy were estimated for the endpoints of death, 
death/MI/stroke, and subsequent procedures, subsequent PCIs, and subsequent CABGs based on 
Cox proportional hazards regression models. Baseline self-efficacy was coded as a dichotomous 
predictor and the clinical outcomes over a period of five years were included. In order to 
estimate the effect of changing self-efficacy over time within the BARI 2D trial, the self-efficacy 
change scores from baseline to Year 1 were used as a predictor variable for cardiovascular 
outcomes occurring over the subsequent four years of follow-up. Each model was adjusted for 
the study design variables, assigned prompt revascularization (vs. medical therapy), assigned 
insulin providing drugs (vs. insulin sensitizing drugs), and the randomization stratification of 
intended CABG (vs. PCI). The first set of models only adjusted for the study design variables. 
The second set of models adjusted for the study design variables, as well as demographic and 
clinical confounding variables. Cox models were created for the overall population and for each 
cardiac treatment arm individually.  
Mixed models were conducted with the presence of angina symptoms as the outcome 
variable and time (follow-up years) as repeated measures. The models controlled for 
revascularization strata (CABG vs. PCI), cardiovascular treatment (prompt revascularization vs. 
medical therapy), and glycemic therapy (insulin providing vs. insulin sensitizing), where 
appropriate. There were tests for interactions between the self-efficacy predictor variable and 
cardiac treatment. 
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 5.6 RESULTS 
There were 1,817 patients with a self-efficacy assessment at baseline and 1,526 of these patients 
had measures at Year 1 (Figure 19). The mean baseline self-efficacy score was 7.71±1.83; 
however, the distribution was skewed and not normally distributed. The mean change in self-
efficacy score from baseline to Year 1 was -0.175±1.93 (Figure 20), and the change score 
distribution was approximately normal. Missing baseline covariate data (with the exception of 
self-efficacy) were replaced by the mean value, when the percent missing did not exceed 5% 
(Table 16). 
Self-efficacy was categorized by quartiles (Table 17). The ranges of the four quartiles 
varied greatly. Upon examination of the quartiles of self-efficacy, a consistent pattern emerged 
such that the Poor group contrasted markedly with the Fair-Excellent groups. Therefore, self-
efficacy was analyzed as a dichotomous variable (Poor vs. Fair/Good/Excellent). All analyses 
were also conducted using self-efficacy as a continuous variable.  Abiding by the direction of the 
self-efficacy assessment’s author, the self-efficacy variable was not transformed (Lorig, 1996) 
(personal communication between Sansing and Lorig via e-mail, 2007).  In addition, in order to 
account for the effect of participation in BARI 2D on the patients’ self-efficacy, we examined 
change in self-efficacy from baseline to Year 1 as a predictor variable. 
 Patients with Poor self-efficacy and those with higher self-efficacy had significantly 
different demographic and clinical profiles at baseline (Table 18). Patients with Poor self-
efficacy were less likely to be male, White nH, to complete a post high school education, and had 
a lower history of cancer. They had higher mean HbA1c, were more likely to have neuropathy 
symptoms, had a longer duration of T2DM, increased use of insulin, had a higher rate of 
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 peripheral artery disease, used more hypertension drugs, and had high LDL, a high albumin 
creatinine ratio (renal impairment), and an increased history of congestive heart failure requiring 
treatment. There were no differences in self-efficacy in randomized treatment and assignment to 
CABG, which indicates a balanced study design. 
Baseline self-efficacy was not related to all-cause mortality and subsequent CABG 
(Table 19). Higher self-efficacy was associated with lower rates of death/MI/stroke (five year 
Kaplan Meier event rates: 20.9% vs. 27.3%, p=0.01; Figure 21a), fewer subsequent procedures 
(35.1% vs. 42.7%, p=0.003), and fewer PCI procedures (23.6% vs. 33.6%, p<.001) in the overall 
BARI 2D population. The difference in the death/MI/stroke rate by self-efficacy group was 
significant among patients randomized to medical therapy (p=0.01), but not among those 
randomized to revascularization (p=0.27). The interaction between treatment groups and baseline 
self-efficacy was not significant (p=0.39).  In both the medical and the revascularization groups, 
patients with Poor self-efficacy had higher rates of subsequent procedures compared to those 
with higher self-efficacy, but the subsequent revascularization rates were consistently higher in 
the medical therapy randomized treatment group (Figure 21b). The Kaplan-Meier curves for 
death/MI/stroke and subsequent procedures for patients with Poor and Fair-Excellent self-
efficacy show that the difference in the cumulative event rates for these outcomes between the 
baseline self-efficacy groups continue to separate over the five year follow-up. 
Poor baseline self-efficacy, when adjusted for change in self-efficacy, was not 
significantly associated with death in this population (Table 20).  Poor self-efficacy at baseline 
was associated with an increased risk of death/MI/stroke (hazard ratio [HR]=1.34, p=0.01), 
subsequent procedures (HR=1.30, p=0.004), and subsequent PCIs (HR=1.43, p<.001) over a 5 
year period. These associations were attenuated after adjusting for baseline variables; and self-
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 efficacy was independently associated with subsequent PCI (HR=1.32, p=0.02), but not 
death/MI/stroke or subsequent procedures.  
When adjusting for self-efficacy, several study design variables were related to an 
increased risk of subsequent revascularization procedures (Table 20). Immediate 
revascularization and randomization to the CABG stratum were associated with a decreased risk 
of subsequent procedure and subsequent PCI compared to medical therapy and PCI stratum. 
When adjusted for baseline covariates, the association between the CABG stratum and 
subsequent PCI was no longer significant. CABG was associated with approximately 3 times the 
risk for subsequent CABG. 
Mixed models were created to estimate the effect of self-efficacy on angina over time 
(Table 21). The models in Set 1 adjust for time only, and the models in Set 2 adjust for time, 
study treatment, and baseline variables (see Methods). Poor self-efficacy is the main predictor 
variable in the top half of the tables, and change in self-efficacy is the main predictor in the 
bottom half. Better baseline self-efficacy was associated with an 11% (p<.001) decrease in the 
risk of angina; however, this association did not persist after adjusting for treatment and baseline 
covariates. A decrease in self-efficacy from baseline to Year 1 was associated with a 9% 
increased risk of angina (p<.001), but this association did not remain significant after adjustment 
for treatment and baseline confounders. The association between self-efficacy and angina did not 
vary by randomization to medical therapy or revascularization (i.e., none of the interaction p-
values for self-efficacy and cardiac treatment were significant; all p-values >0.40). Time was 
associated with a decreased risk of angina when controlling for baseline self-efficacy (OR=0.91 
per year, p<.001) and change in self-efficacy (OR=0.87, p<.001). Study design variables were 
not related to an increased risk of angina in these models. 
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 5.7 DISCUSSION 
The primary goal of this study was to examine the association between baseline self-efficacy and 
cardiovascular outcomes in patients with both T2DM and CAD. Poor self-efficacy and a 
decrease in self-efficacy from baseline to Year 1 were associated with several cardiac outcomes. 
Although no association between baseline self-efficacy and the primary endpoint of all-cause 
mortality was established in multivariate analyses, we did observe several critical associations 
with secondary outcomes. First, Poor baseline self-efficacy was associated with higher 5-year 
cardiac event rates compared to Fair/Good/Excellent self-efficacy. Second, a decrease in self-
efficacy from baseline to Year 1 was associated with greater adverse outcomes. Compared to 
moderate change, this decrease was associated with a more than two-fold risk of death, a greater 
risk of death/MI/stroke after adjustments for baseline covariates, and a greater risk of angina 
when adjusted for time only.  
Overall and within patients randomized to medical therapy, poor baseline self-efficacy 
was independently associated with higher 5-year rates of death/MI/stroke, subsequent 
procedures, subsequent PCI’s, and angina than Fair-Excellent self-efficacy. The primary findings 
are similar to those of Sarkar et al. (2009), who showed that lower self-efficacy was a powerful 
predictor of increased cardiac burden, including heart failure and all cause mortality. After 
adjustments, the increase in heart failure and mortality were mainly attributed to poorer baseline 
cardiac function. In BARI 2D, only when change in self-efficacy (from baseline to Year 1) was 
incorporated into the model did self-efficacy become associated with all-cause mortality. 
Because self-efficacy is a state as opposed to a trait, and changes over time are based on 
successes and failures, a cross-sectional observation of self-efficacy is an inadequate predictor of 
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 death. It is more important to capture evidence of improvement, stability, and decline in one’s 
confidence. This variable of “change” is valuable because it shows the effect of participation in 
BARI 2D and the direction of the state. For instance, two people may enter the study with a 
baseline self-efficacy score of 8 and similar baseline profiles. By using these baseline scores as 
the predictor, it would be premature to conclude that these patients have a similar risk of death. 
Further, consider that by Year 1, one patient’s self-efficacy increases to 10 and the other 
patient’s score may decrease to 6. Here, the “change” in scores over time has proven to be a 
stronger predictor of death as the second patient is at higher risk for death. 
In line with the findings by Sarkar et al. (2009), poor baseline self-efficacy was 
associated with greater cardiac symptoms and burden, as defined by death/MI/stroke, angina, 
subsequent revascularization procedures, and subsequent PCI. When factoring in serious non-
fatal adverse events of MI and stroke as outcomes, baseline self-efficacy became a strong 
predictor. The association between self-efficacy and death/MI/stroke persisted after adjustments 
for randomized treatment groups and baseline covariates. This demonstrates the strength of a 
person’s self-confidence in the management and prevention of serious cardiac outcomes that are 
potentially debilitating and fatal. In addition, Joekes et al. (2007) stated that low self-efficacy 
was a barrier to seeking punctual treatment for an MI, thereby increasing the risk for associated 
adverse prognoses. This further emphasizes the serious nature of poor self-confidence in a 
patient population at increased risk for adverse events and why these patients are at an increased 
risk of death. It also appeared that patients with poor baseline self-efficacy and a decrease in 
score from baseline to Year 1 were at higher risk for angina. However these associations were 
primarily explained by baseline covariates. 
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  In BARI 2D, poor self-confidence combined with poorer baseline function lead to a 
greater risk of having a subsequent procedure. This was especially significant in the patients 
randomized to medical therapy in which a subsequent procedure was defined as their very first 
procedure in BARI 2D. Patients randomized to medical therapy were only revascularized in the 
event of worsening cardiac conditions, as opposed to patients randomized to prompt 
revascularization who received a procedure shortly after enrollment into the study. Therefore, 
patients in medical therapy were more likely to have subsequent procedures. In the medical 
therapy arm, more than half of the patients with poor self-efficacy received a subsequent 
procedure compared to 47% of patients with better self-efficacy. In addition, subsequent 
procedures included both CABG and PCI. PCI is a revascularization procedure that can be 
performed multiple times, as opposed to CABG which is infrequently performed more than once. 
Therefore, the association between self-efficacy and subsequent procedures is primarily 
explained by the PCI. This may explain why there was no association between self-efficacy and 
subsequent CABG.  
In conclusion, in patients with comorbid T2DM and CAD, poor baseline self-efficacy 
was associated with an increased risk of death/MI/stroke, subsequent revascularization 
procedures, and subsequent PCIs. In addition, a decrease in self-efficacy from baseline to Year 1 
was associated with death and death/MI/stroke. These results must be seen in light of several 
limitations. First, the patient population is one that is eligible for elective revascularization. 
Therefore, their clinical status is less severe than patients who must undergo immediate 
revascularization. The patients in the study may have had better self-efficacy than the 
aforementioned set of patients. Second, the self-efficacy assessment did not specifically 
distinguish between the management of T2DM and CAD. It generalized the management of the 
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 diseases, therefore we were not able to study self-efficacy regarding each disease separately. 
Third, the effects of self-efficacy may have been due to depressive symptoms, which are clearly 
established as risk factors for CAD morbidity, diabetes, and mortality (Rutledge, et al., 2006).  
We could not adjust for depressive symptoms in our analyses because the assessment of 
depressive symptoms (CES-D) was incorporated into the BARI 2D protocol in February 2006, 
after the study began. These data were collected annually at Years 3-6.  
These limitations are balanced by several important strengths. First, this study was a 
prospective, randomized, controlled clinical trial with a large study population. We were able to 
prospectively observe self-efficacy and other variables at baseline and follow their change 
throughout the study. Second, because the treatment for T2DM and CAD was randomized, 
allocation of the patient population to treatment groups was not biased by demographic or 
clinical status. Third, the study population was demographically diverse, which increased the 
generalizability of the results. Fourth and most importantly, this study is the first non-
observational study to examine the association between self-efficacy and mortality. This study 
demonstrated that a decrease in self-efficacy more than doubles one’s risk for death.  
This research is of great public health significance because it provides evidence of 
another psychosocial factor that can impact mortality. The increase in subsequent procedures 
associated with poor self-efficacy can impose a significant financial burden on the currently 
fiscally exhausted medical field. There is no research published to date that measures the effect 
of self-efficacy improvement programs on mortality. Because we have examined the impact of 
change in self-efficacy on mortality, the next steps for research in this field should focus on 
addressing the change in clinical variables over time in conjunction with the change in self-
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 efficacy. This would allow one to assess how the feedback loop is associated with the cardiac 
outcomes.  
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 5.8 TABLES AND FIGURES FOR PAPER 3 
Table 16. Missing values and replaced means  
Variable Mean Missing N Action 
Education 4.50 24 2344 Replaced with mean 
Current cigarette smoker 0.13 8 2360 Replaced with mean 
Malignancy 0.08 3 2365 Replaced with mean 
HbA1c % 7.66 6 2362 Replaced with mean 
 HbA1c ≥ 8% 0.35 72 2296 Replaced with mean 
Probable neuropathy: screening MNSI ≥ 7 0.16 29 2339 Replaced with mean 
Neuropathy: clinical MNSI > 2 0.50 26 2342 Replaced with mean 
Insulin use at baseline 0.28 4 2364 Replaced with mean 
Duration of Type 2 diabetes mellitus 10.44 23 2345 Replaced with mean 
Angina category within 6 weeks 4.00 4 2364 Replaced with mean 
History of CHF requiring treatment 0.07 20 2348 Replaced with mean 
History of MI 0.32 40 2328 Replaced with mean 
Hypercholesterolemia requiring treatment 0.82 32 2336 Replaced with mean 
Sitting systolic blood pressure average 131.70 35 2333 Replaced with mean 
Sitting systolic blood pressure > 140 0.27 35 2333 Replaced with mean 
Sitting diastolic blood pressure average 74.51 36 2332 Replaced with mean 
Low density lipids mg/dl 96.20 131 2237 Replaced with mean 
Body mass index 31.74 28 2340 Replaced with mean 
Key: Hba1c – hemoglobin A1c, MNSI – Michigan neuropathy screening instrument
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 Table 17. Quartiles of baseline self-efficacy  
 Baseline Self efficacy score (0-10),  N=1817 
Category: Baseline self-efficacy scores N Mean Standard Deviation Minimum Maximum 
1) Poor:  1.0-6.7 449 5.15 1.23 1.00 6.67 
2) Fair: 6.75-8.0 529 7.47 0.43 6.75 8.00 
3) Good: 8.25-9.0 402 8.66 0.28 8.25 9.00 
4) Excellent: 9.25-10.0 437 9.80 0.28 9.25 10.00 
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 Table 18. Baseline demographics and clinical status by baseline self-efficacy scores  
 
Total 
(N=1,817) 
Poor SE:  
Score 1 - 6.7 (N=449) 
Fair - Excellent SE: 
Score 6.75-10 
(N=1,368) 
p-
value 
Male, % 71.6 66.4 73.3 0.005 
Race/Ethnicity, %     
   White nH 64.1 53.2 67.6 <.001 
   Black nH 18.9 20.7 18.3  
   Hispanic 11.5 18.9 9.1  
   Asian nH 4.8 5.8 4.5  
   Other nH 0.7 1.3 0.5  
Age at study entry, mean, SD 62.6, 9.0 62.0, 8.8 62.9, 9.0 0.08 
Body mass index, mean, SD 32.5, 6.1 32.8, 6.6 32.4, 5.9 0.30 
United States site, % 80.6 79.5 80.9 0.51 
Current cigarette smoker, % 13.1 14.3 12.7 0.41 
Post high school education, % 48.4 33.2 53.4 <.001 
History of malignancy, % 9.6 7.1 10.5 0.04 
HbA1c %: mean, SD 7.6, 1.5 7.7, 1.6 7.5, 1.5 0.003 
HbA1c ≥ 8%, % 32 36.3 30.5 0.02 
MNSI clinical score, mean, SD 2.5, 1.7 2.7, 1.7 2.4, 1.7 0.005 
Probable neuropathy: screening MNSI ≥ 7, % 15.9 24.7 13 <.001 
Duration of T2DM, mean, SD 10.7, 8.8 11.6, 9.2 10.4, 8.7 0.01 
Currently taking insulin, % 30.3 39.3 27.4 <.001 
Ankle brachial index categories, %     
   ≤0.9 (low) 17.6 19.7 16.9 0.26 
   0.91-1.30 67.1 65.2 67.7  
   >1.3 (high) 8.1 6.7 8.5  
   Non-Compressible arteries 7.2 8.4 6.8  
Peripheral artery disease, % 25.5 29.6 24.1 0.02 
Chronic renal dysfunction, % 3.7 3.8 3.7 0.91 
Number of hypertension drugs, mean, SD 2.3, 1.0 2.5, 1.0 2.2, 1.0 <.001 
Sitting systolic BP average, mean, SD 130.8, 18.7 132.0, 20.1 130.4, 18.3 0.14 
Systolic BP > 140, % 25.5 27.6 24.8 0.25 
Total cholesterol ≥ 200 mg/dl, % 24.4 26.7 23.6 0.18 
Low density lipids mg/dl, mean, SD 98.6, 36.5 101.2, 40.6 97.8, 34.9 0.12 
Low density lipids ≥ 100 mg/dl, % 42.1 46.3 40.7 0.04 
Albumin creatinine ratio > 30 mg/g, % 33.4 38.2 31.7 0.02 
History of MI, % 29.5 32.8 28.5 0.09 
History of CHF with treatment, % 8 12.2 6.6 <.001 
Proximal LAD ≥ 50% stenosis, % 12.4 10.5 13 0.16 
Three vessel disease, % 28.6 27.7 28.9 0.62 
Insulin Providing, % 50.1 51.9 49.6 0.39 
Prompt Revascularization, % 49.4 48.3 49.8 0.59 
CABG, % 24.3 21.4 25.3 0.09 
Key: BP - blood pressure, CABG – coronary artery bypass graft, CHF – congestive heart failure, LAD – left anterior 
descending, MI – myocardial infarction, MNSI – Michigan neuropathy screening instrument, SD – standard 
deviation, T2DM – Type 2 diabetes mellitus 
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Table 19. Five year event rates for BARI 2D cardiovascular endpoints stratified by baseline 
self-efficacy score and by randomized cardiac treatment  
Outcome Cardiac Treatment Poor (n=449) 
Fair-Excellent 
(n=1,368) p-value 
Death ALL 12.7% 10.0% 0.12 
 MED 12.4% 10.1% 0.27 
 REV 13.0% 9.9% 0.27 
Death/MI/Stroke ALL 27.3% 20.9% 0.01 
 MED 30.1% 20.8% 0.01 
 REV 24.3% 20.9% 0.27 
Subsequent Procedure ALL 42.7% 35.1% 0.003 
 MED 52.6% 44.9% 0.02 
 REV 32.1% 25.0% 0.08 
Subsequent PCI ALL 33.6% 23.6% <.001 
 MED 40.1% 28.0% 0.002 
 REV 26.8% 19.1% 0.06 
Subsequent CABG ALL 12.2% 14.7% 0.58 
 MED 16.5% 20.7% 0.54 
 REV 7.5% 8.5% 0.86 
 
Key: CABG – Coronary artery bypass graft, MED – medical therapy, MI – myocardial infarction, PCI – 
percutaneous coronary intervention, REV – prompt revascularization 
 Table 20. The hazard ratio of cardiovascular outcomes for self efficacy and change in self-
efficacy based on Cox proportional hazard regression models  
   
Set 1: Adjusted for study design 
variables 
Set 2: Adjusted for study design 
variables and baseline covariates* 
   Baseline SE 
Baseline SE + 
Change Baseline SE 
Baseline SE + 
Change 
Outcome Predictors HR P-Value HR P-Value HR P-Value HR P-Value 
Death Poor Self-efficacy 1.26 0.11 1.47 0.01 1.04 0.79 1.24 0.22 
  SE Score Decrease ≥1.5 2.13 <.001   2.32 <.001 
  SE Score Increase ≥1.5 0.97 0.88   0.91 0.70 
  Assigned IP treatment 0.98 0.86 0.97 0.82 1.04 0.78 1.04 0.80 
  Assigned REV treatment 1.03 0.82 1.01 0.93 1.02 0.87 0.99 0.95 
  
Randomization stratum 
CABG 1.10 0.53 1.14 0.39 0.89 0.49 0.93 0.64 
Death/ Poor Self-efficacy 1.34 0.01 1.43 0.02 1.22 0.10 1.42 0.01 
 MI/Stroke SE Score Decrease ≥1.5 1.17 0.30   1.79 <.001 
  SE Score Increase ≥1.5 0.94 0.74   0.86 0.39 
  Assigned IP treatment 1.07 0.47 1.09 0.51 1.15 0.17 1.15 0.17 
  Assigned REV treatment 0.95 0.57 0.76 0.03 0.92 0.43 0.90 0.30 
  
Randomization stratum 
CABG 1.16 0.17 1.08 0.60 1.01 0.92 1.05 0.71 
Sub. 
Procedure Poor Self-efficacy 1.30 0.004 1.23 0.11 1.20 0.06 1.13 0.27 
  SE Score Decrease ≥1.5 0.93 0.60   1.16 0.12 
  SE Score Increase ≥1.5 1.03 0.84   1.29 0.05 
  Assigned IP treatment 1.10 0.22 1.30 0.01 1.11 0.21 1.12 0.20 
  Assigned REV treatment 0.49 <.001 0.54 <.001 0.49 <.001 0.49 <.001 
  
Randomization stratum 
CABG 0.82 0.04 0.71 0.01 0.81 0.06 0.81 0.05 
Sub. PCI Poor Self-efficacy 1.43 <.001 1.39 <.001 1.32 0.02 1.26 0.07 
  SE Score Decrease ≥1.5 1.26 0.03   1.17 0.16 
  SE Score Increase ≥1.5 1.21 0.18   1.22 0.18 
  Assigned IP treatment 1.14 0.18 1.13 0.19 1.17 0.11 1.18 0.11 
  Assigned REV treatment 0.60 <.001 0.60 <.001 0.58 <.001 0.58 <.001 
  
Randomization stratum 
CABG 0.29 <.001 0.29 <.001 0.29 <.001 0.29 <.001 
Sub. CABG Poor Self-efficacy 0.95 0.74 0.97 0.85 0.85 0.34 0.84 0.34 
  SE Score Decrease ≥1.5 1.11 0.49   1.05 0.78 
  SE Score Increase ≥1.5 0.99 0.95   1.06 0.78 
  Assigned IP treatment 1.01 0.92 1.01 0.94 1.01 0.94 1.01 0.95 
  Assigned REV treatment 0.36 <.001 0.36 <.001 0.39 <.001 0.39 <.001 
  
Randomization stratum 
CABG 2.91 <.001 2.93 <.001 2.89 <.001 2.88 <.001 
Key: H.R. – hazard ratio, MED – medical therapy, REV – prompt revascularization, SE – self-efficacy, Sub. - subsequent 
*Adjusted for baseline values of age, sex, race/ethnicity, insulin use, post high school education, cigarette use, HbA1c, clinical 
neuropathy, duration of diabetes, peripheral artery disease, micro albuminuria, history of MI, history of congestive heart failure, 
and proximal LAD with ≥50% stenosis.  
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 Table 21. The odds ratio of angina for baseline self-efficacy and change in self-efficacy 
from mixed models 
 
  Set 1: Adjusted for Time Set 2: Adjusted for Time, Treatment and 
Baseline Variables* 
Variable Estimate OR p-value Estimate OR p-value 
Poor baseline self-efficacy 0.11 1.11 <.001 0.03 1.03 0.83 
Follow up years 1 - 5 (per 1 yr) -0.04 0.96 <.001 -0.10 0.91 <.001 
Angina at baseline    0.07 1.07 0.58 
Assigned insulin providing treatment    -0.03 0.97 0.76 
Assigned prompt revascularization    -0.22 0.80 0.08 
CABG    -0.01 0.99 0.97 
Variable Estimate OR p-value Estimate OR p-value 
Poor baseline self-efficacy 0.13 1.14 <.001 0.17 1.18 0.54 
SE Score Decrease ≥1.5 0.07 1.07 0.001 0.001 1.00 1.00 
SE Score Increase ≥1.5 -0.02 0.98 0.58 -0.24 0.79 0.33 
Follow up years 2 - 5 (per 1 yr) -0.04 0.96 <.001 -0.14 0.87 <.001 
Angina at baseline    -0.21 0.81 0.19 
Assigned insulin providing treatment    -0.11 0.90 0.49 
Assigned prompt revascularization    -0.15 0.86 0.36 
CABG    0.005 1.00 0.98 
Key: OR – odds ratio, SE – self-efficacy, yr - year 
*Adjusted for baseline values of angina, age, sex, race/ethnicity, insulin use, post high school education, cigarette use, HbA1c, 
clinical neuropathy, duration of diabetes, peripheral artery disease, micro albuminuria, history of MI, history of congestive heart 
failure, and proximal LAD with ≥50% stenosis.  
No interaction p-values for self-efficacy and cardiac treatment were significant (p’s >0.40), therefore association between self-
efficacy and angina did not differ by treatment. 
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Figure 19. Population flowchart for Aim 3 
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Figure 20. The distribution of the baseline self-efficacy score and change in self-efficacy 
score from baseline to Year 1 
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Figure 21. Survival and freedom from event distribution by self-efficacy scores and cardiac 
therapy  
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 6.0  CONCLUSION 
The primary goal of these analyses was to determine the relationship between self-efficacy and 
clinical risk factors, treatment, and outcomes of patients with comorbid CAD and T2DM. The 
first paper indicated that in patients with self-efficacy scores ≤8, randomized treatment for CAD 
and T2DM and the type of assigned revascularization procedure did not affect the patients' 
confidence in managing their conditions throughout the BARI 2D trial. These patients, however, 
did benefit from their participation in BARI 2D, as reflected by an increase in self-efficacy over 
time. Senuzun et al. (2006) demonstrated that self-efficacy enhancing programs do in fact 
increase self-efficacy and improve clinical risk factors in patients. BARI 2D, with its coordinated 
clinical care, lifestyle risk factor program, and empowering clinical staff, may have 
simultaneously improved the patients confidence in being able to manage their medical 
conditions.  
In the second paper, the associations between the clinical risk factors of HbA1c, lipids, 
blood pressure, physical functioning, and BMI and self-efficacy were examined. Over the course 
of the study, better self-efficacy was related to improved glycemic control and physical 
functioning. In line with Bandura’s theory of self-efficacy, a feedback loop was shown in which 
risk factors were associated with future self-efficacy, which in turn was associated with future 
risk factors (A. Bandura, 1977). Compared to the racial/ethnic minorities, the feedback loop was 
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 strongly observed in White nH patients. Black nH patients were more likely than White nH and 
Hispanic patients to have lower self-efficacy as HbA1c control improved, indicating a form of 
health pessimism in Black nH patients. The discrepancy in the patterns in the Black nH patients 
is mirrored in the study by Martin et al. (2004) that showed that high self-efficacy was not 
associated with weight loss in Black women. Despite high self-efficacy, these participants’ mean 
weight did not increase or decrease. It is not noted in our study, nor in the study by Martin et al. 
(2004), if self-efficacy was associated with the patients’ perceived stage of change (A. Bandura, 
1997). Patients with higher self-efficacy may have believed they have the confidence to manage 
their condition, but may not have been in the stage of change that prompts them to initiate these 
behaviors. Future research regarding self-efficacy should also measure the patient’s stage of 
change.  
The third set of analyses examined the association between self-efficacy and cardiac 
outcomes. Poor baseline self-efficacy (≤6.7) was associated with an increased risk of 
death/MI/stroke, subsequent revascularization procedures, and subsequent PCIs, but was not 
associated with death, subsequent CABGs, and angina. The association between self-efficacy 
and death/MI/stroke remained significant after adjustment for baseline confounders, while the 
other two associations became non-significant. A decrease in self-efficacy from baseline to Year 
1 was associated with the primary and secondary outcomes of death and death/MI/stroke. This 
stresses the importance of developing initiatives to boost patients’ confidence in their disease 
management through diabetes and CAD management programs that emphasize positive feedback 
and social support. 
 Our analyses demonstrated strong results because our patients were part of a large-scale, 
prospective, randomized clinical trial. Previous research by Sarkar et al. laid the groundwork for 
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 research in this area through the use of patients enrolled in the Heart and Soul observational 
study (Sarkar, et al., 2007; Sarkar, et al., 2009; Sarkar, et al., 2006). The research from the Heart 
and Soul study showed significant associations between self-efficacy in cardiac control, 
symptoms, and outcomes. However, it was limited by non-randomized cardiac treatment. The 
BARI 2D study had the advantage of randomizing the treatment received in a large, diverse 
patient population, and following these patients over a mean period of 5.3 years. Despite 
differences in the study design, both studies showed the influence of self-efficacy on cardiac risk 
factors and outcomes. The culmination of results from both studies is generalizable to patients 
eligible for elective surgery and to those eligible for non-elective surgery. 
6.1 PUBLIC HEALTH IMPACT 
Despite treatment differences for T2DM and CAD in BARI 2D, self-efficacy was associated 
with clinical risk factors and cardiac outcomes in patients with CAD and T2DM. These results 
have multiple public health implications within the financial system, health care system, and on 
an individual level. 
Changes in health care reform have an increased focus on preventative health care and 
provision of health care, regardless of pre-existing conditions 
(U.S._Department_of_Health_&_Human_Services, 2010). In 2009, the direct (medical 
expenses) and indirect (lost productivity, disability) costs of CAD and stroke in the US totaled 
approximately $475.3 billion (NHLBI, 2009). The total costs for diabetes in 2007 were $174 
billion (ADA, 2009). The prevention, progression, and course of T2DM and CAD are partially 
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modifiable through self-management. The health care system should address the issue of 
increasing a patient’s confidence, which in turn can decrease cardiac morbidity and mortality, 
and possibly decrease the financial impact of these leading diseases in the US. 
From the perspective of health care professionals, our research shows that assessing a 
person’s confidence in managing their conditions not only serves as a strong predictor of clinical 
risk factors, but is indicative of a person’s clinical history. From the patients’ perspective, it 
stresses the importance of improving and maintaining self-confidence in the face of comorbid 
conditions to improve health and prevent serious complications. The source of confidence 
maintenance can be internal or sought from external sources such as caregivers, loved ones, and 
learning from success stories through others with the same conditions. This is especially 
important for minorities, who are faced with multiple health disparities in diagnoses, treatment, 
and outcomes, and report lower self-efficacy as compared to Whites. For some patients, T2DM 
and CAD are seen as conditions they can conquer, and these patients make efforts to do so. For 
other patients, these diseases are seen in a fatalist manner, in which futile efforts do not alleviate 
the advancement of death.  
In conclusion, future research in this area should focus on the impact of public health 
initiatives to increase a patient’s confidence in managing and conquering their diseases and the 
financial impact of these initiatives on society. In those with a history of poor clinical control, 
these initiatives must focus on shifting the patients’ sense of learned helplessness into one of 
empowerment. 
 APPENDIX A: SELF EFFICACY ASSESSMENT* 
SECTION E: QUALITY OF LIFE 
4.              We would like to know how confident you are in doing certain activities. For each of the following 
questions, please circle the number that corresponds to your confidence that you can do these things regularly at the 
present time. 
 
4.1              Having diabetes and heart disease often means doing different tasks and activities to manage your 
condition. How confident are you that you can do all the things necessary to manage your condition on a regular 
basis? 
Not at all                                                                                        Totally 
Confident     1     2     3     4    5     6     7     8     9     10              Confident 
 
How confident are you that you can… 
4.2              Do the different tasks and activities needed to manage your diabetes and heart disease so as to reduce 
your need to see a doctor? 
Not at all                                                                                       Totally 
Confident     1     2     3     4    5     6     7     8     9     10              Confident 
 
4.3              Reduce the emotional distress caused by your diabetes and heart disease so that it does not affect your 
everyday life? 
Not at all                                                                                      Totally 
Confident     1     2     3     4    5     6     7     8     9     10              Confident 
 
4.4              Do things other than just taking medication to reduce how much your diabetes and heart disease affect 
your everyday life? 
Not at all                                                                                         Totally 
Confident     1     2     3     4    5     6     7     8     9     10              Confident 
* Reprinted from BARI 2D Data Forms Manual (BARI_2D_Coordinating_Center, 2002). 
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APPENDIX B: REASONS FOR LOST-TO-FOLLOW UP IN PAPER 1 
Follow-up period Type of event                           
  N                                                
% 
Year 1 
(N=889) 
Year 2 
(N=873) 
Year 3 
(N=827) 
Year 4 
(N=711) 
4 3 1 2 Inactivation: Rescission of consent 
40 30 10 20 
3 3 0 1 Inactivation: Complete 
42.86 42.86 0 14.29 
8 4 1 0 Inactivation: AFD 
61.54 30.77 7.69 0 
0 0 0 2 Reactivation 
0 0 0 100 
15 12 86 667 Vital status - alive 
1.92 1.54 11.03 85.51 
7 3 2 5 Vital status - unknown 
41.18 17.65 11.76 29.41 
4 4 73 606 Close out 
0.58 0.58 10.63 88.21 
16 15 22 39 Death 
17.39 16.3 23.91 42.39 
Total* 57 44 185 1322 
*Events are not mutually exclusive.
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